[Federal Register Volume 63, Number 38 (Thursday, February 26, 1998)] [Notices] [Pages 9795-9843] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 98-4916] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 98N-0046] Comprehensive List of Current Guidance Documents at the Food and Drug Administration AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA) is publishing a comprehensive list of all guidance documents currently in use at the agency. FDA committed to publishing this list in its February 1997 ``Good Guidance Practices'' (GGP's), which set forth the agency's policies and procedures for the development, issuance, and use of guidance documents. This list is intended to inform the public of the existence and availability of all current guidance documents, including those documents that were issued prior to the adoption of the GGP's. DATES: General comments on this list and on agency guidance documents are welcome at any time. ADDRESSES: Submit written comments to the Dockets Management Branch (HFD-305), Food and Drug Administration, 12420 Parklawn Dr., rm 1-23, Rockville, MD 20857. Information on where to obtain single copies of a listed guidance document is provided for each agency center individually in the specific center's list of guidance documents. FOR FURTHER INFORMATION CONTACT: Lisa L. Barclay, Office of Policy (HF- 22), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-3360. SUPPLEMENTARY INFORMATION: I. Background In the Federal Register of February 27, 1997 (62 FR 8961), FDA published a notice announcing its ``Good Guidance Practices'' (GGP's), which set forth the agency's policies and procedures for the development, issuance, and use of guidance documents. The agency adopted the GGP's to ensure public involvement in the development of guidance documents and to enhance public understanding of the availability, nature, and legal effect of such guidance. As part of FDA's effort to ensure meaningful interaction with the public regarding guidance documents, the agency committed to publish a comprehensive list of all guidance documents that are currently in effect. This comprehensive list is maintained on the FDA World Wide Web home page. The list will be updated and published annually in the Federal Register. FDA also has committed to publish quarterly a Federal Register notice that lists all guidance documents that were issued and withdrawn during that quarter. FDA also has undertaken to publish, on a quarterly basis, a list of all new ``Level 2'' guidance documents issued by the agency under the GGP's. In a separate notice in a future issue of the Federal Register, FDA will publish its first quarterly update including a list of Level 2 guidance documents issued during that quarter. The following list of guidance documents represents all guidances issued by FDA that are currently in effect. The documents are organized by the issuing Center or Office within FDA, and are further grouped by the intended users or regulatory activities to which they pertain. Dates provided in the following list refer to the date of issuance or, where applicable, the date of last revision of the document. Document numbers are provided where available, and guidance documents that are still in draft form and on which public comment has been requested are so identified. This cumulative list includes guidance documents that were issued prior to the adoption of the GGP's. At the time such documents are substantively revised, FDA will update them to include the standard guidance elements and nomenclature described in the GGP's. II. Guidance Documents Issued by the Center for Biologics Evaluation and Research (CBER) [[Page 9796]] ---------------------------------------------------------------------------------------------------------------- How to Obtain a Hard Copy of Grouped by Intended the Document (Name and Name of Document Date of Issuance User or Regulatory Address, Phone, FAX, E-mail, Activity or Internet) ---------------------------------------------------------------------------------------------------------------- Requirements for Infrequent August 27, 1982 FDA Regulated Office of Communication, Plasmapheresis Donors Industries Training and Manufacturers Assistance, 1401 Rockville Pike, Rockville, MD 20852- 1448, 301-827-1800 or 1-800- 835-4709, FAX Information System: 1-888-CBER-FAX (within U.S.) 301-827-3844 (outside U.S. and local to Rockville, MD) Internet access: http://www.fda.gov/ cber/ Recommendations to Decrease the Risk March 24, 1983 Do Do of Transmitting AIDS from Plasma Donors Deferral of Blood Donors Who Have February 28, 1984 Do Do Received the Drug Accutane (isotretinoin/Roche); 13-cis-retinoic acid) Equivalent Methods for Compatibility December 14, 1984 Do Do Testing Plasma Derived from Therapeutic Plasma December 14, 1984 Do Do Exchange Reduction of the Maximum Platelet June 2, 1986 Do Do Storage Period to 5 Days in an Approved Container Deferral of Donors Who Have Received November 25, 1987 Do Do Human Pituitary-Derived Growth Hormone Recommendations for the Management of December 2, 1987 Do Do Donors and Units That Are Initially Reactive for Hepatitis B Surface Antigen (HBsAg) Extension of Dating Period for Storage December 4, 1987 Do Do of Red Blood Cells, Frozen To Licensed In-Vitro Diagnostic December 23, 1987 Do Do Manufacturers: Handling of Human Blood Source Materials Recommendations for Implementation of April 6, 1988 Do Do Computerization in Blood Establishments Control of Unsuitable Blood and Blood April 6, 1988 Do Do Components Discontinuance of Prelicensing July 7, 1988 Do Do Inspection for Immunization Using Licensed Tetanus Toxoid and Hepatitis B and Rabies Vaccines Physician Substitutes August 15, 1988 Do Do To Licensed Manufacturers of Blood August 26, 1988 Do Do Grouping Reagents: Criteria for Exemption of Lot Release To Manufacturers of HTLV-I Antibody October 18, 1988 Do Do Test Kits: Antibody to Human T-Cell Lymphotropic Virus, Type I (HTLV-I) Release Panel I HTLV-1 Antibody Testing November 29, 1988 Do Do Use of Recombigen HIV-1 LA Test February 1, 1989 Do Do Guidance for Autologous Blood and March 15, 1989 Do Do Blood Components HTLV-I Antibody Testing July 6, 1989 Do Do Use of Recombigen HIV-1 Latex August 1, 1989 Do Do Agglutination (LA) Test Requirements for Computerization of September 8, 1989 Do Do Blood Establishments Abbott Laboratories' HIVAG-1 Test for October 4, 1989 Do Do HIV-1 Antigen(s) Not Recommended for Use as a Donor Screen Autologous Blood Collection and February 12, 1990 Do Do Processing Procedures Use of Genetic Systems HIV-2 EIA June 21, 1990 Do Do Deficiencies Relating to the March 20, 1991 Do Do Manufacture of Blood and Blood Components Responsibilities of Blood March 20, 1991 Do Do Establishments Related to Errors & Accidents in the Manufacture of Blood and Blood Components Revision to October 26, 1989 Guideline April 17, 1991 Do Do for Collection of Blood or Blood Products from Donors with Positive Tests for Infectious Disease Markers (High Risk Donors) FDA Recommendations Concerning Testing September 10, 1991 Do Do for Antibody to Hepatitis B Core Antigen (Anti-HBc) Disposition of Blood Products Intended September 11, 1991 Do Do for Autologous Use That Test Repeatedly Reactive for Anti-HCV [[Page 9797]] Clarification of FDA Recommendations December 12, 1991 Do Do for Donor Deferral and Product Distribution Based on the Results of Syphilis Testing Revised Recommendations for the April 23, 1992 Do Do Prevention of Human Immunodeficiency Virus (HIV) Transmission by Blood and Blood Products Use of Fluorognost HIV-1 April 23, 1992 Do Do Immunofluorescent Assay (IFA) Revised Recommendations for Testing April 23, 1992 Do Do Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV) Exemptions to Permit Persons with a April 23, 1992 Do Do History of Viral Hepatitis Before the Age of Eleven Years to Serve as Donors of Whole Blood and Plasma; Alternative Procedures (21 CFR 640.120) Changes in Equipment for Processing July 21, 1992 Do Do Blood Donor Samples Nomenclature for Monoclonal Blood September 28, 1992 Do Do Grouping Reagents Volume Limits for Automated Collection November 4, 1992 Do Do of Source Plasma Revision of October 7, 1988 Memo December 16, 1992 Do Do Concerning Red Blood Cell Immunization Programs Recommendations Regarding License July 22, 1993 Do Do Amendments and Procedures for Gamma Irradiation of Blood Products Deferral of Blood and Plasma Donors July 28, 1993 Do Do Based on Medications Revised Recommendations for Testing August 19, 1993 Do Do Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV) Changes in Administrative Procedures September 9, 1993 Do Do Guidance Regarding Post Donation December 10, 1993 Do Do Information Reports Donor Suitability Related to December 22, 1993 Do Do Laboratory Testing for Viral Hepatitis and a History of Viral Hepatitis Recommendations for the Invalidation January 3, 1994 Do Do of Test Results When Using Licensed Viral Marker Assays to Screen Donors Recommendations for Deferral of Donors July 26, 1994 Do Do for Malaria Risk Use of and FDA Cleared or Approved August 5, 1994 Do Do Sterile Docking Device (STCD) in Blood Bank Practices (transmittal memo 8/12/94) (corrects 7/29/94 Memo) Recommendations to Users of Medical December 20, 1994 Do Do Devices That Test for Infectious Disease Markers by Enzyme Immunoassay (EIA) Test Systems Timeframe for Licensing Irradiated February 3, 1995 Do Do Blood Products Revision of 8/27/82 FDA Memo: March 10, 1995 Do Do Requirements for Infrequent Plasmapheresis Donors To All Establishments Performing Red March 14, 1995 Do Do Blood Cell Immunizations: Revised Recommendations for Red Blood Cell Immunization Programs for Source Plasma Recommendations for the Deferral of June 8, 1995 Do Do Current and Recent Inmates of Correctional Institutions as Donors of Whole Blood, Blood Components, Source Leukocytes and Source Plasma Disposition of Products Derived from August 8, 1995 Do Do Donors Diagnosed with, or at Known High Risk for, Creutzfeldt-Jakob Disease Recommendations for Labeling and Use August 8, 1995 Do Do of Units of Whole Blood, Blood Components, Source Plasma, Recovered Plasma or Source Leukocytes Obtained from Donors with Elevated Levels of Alanine Aminotransferase (ALT) [[Page 9798]] Precautionary Measures to Further August 8, 1995 Do Do Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease by Blood and Blood Products Recommendations for Donor Screening August 8, 1995 Do Do with a Licensed Test for HIV-1 Antigen Guidance Concerning Conversion to FDA- November 13, 1995 Do Do Reviewed Software Products Donor Deferral Due to Red Blood Cell December 4, 1995 Do Do Loss During Collection of Source Plasma by Automated Plasmapheresis Additional Recommendations for Donor March 14, 1996 Do Do Screening With a Licensed Test for HIV-1 Antigen Additional Recommendations for Testing May 16, 1996 Do Do Whole Blood, Blood Components, SourcePlasma and Source Leucocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV) Recommendations and Licensure May 29, 1996 Do Do Requirements for Leukocyte-Reduced Blood Products Recommendations for the Quarantine and July 19, 1996 Do Do Disposition of Units from Prior Collections from Donors with Repeatedly Reactive Screening Tests for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human T- Lymphotropic Virus Type I (HTLV-I) Interim Recommendations for Deferral December 11, 1996 Do Do of Donors at Increased Risk for HIV-1 Group O Infection Revised Precautionary Measures to December 11, 1996 Do Do Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) by Blood and Blood Products Interstate Shipment of Interferon for November 21, 1983 Do Do Investigational Use in Laboratory Research Animals or Tests in Vitro Alternatives to Lot Release July 20, 1993 Do Do Application of Current Statutory October 14, 1993 Do Do Authorities to Human Somatic Cell Therapy Products and Gene Therapy Products; Notice Home Specimen Collection Kit Systems February 23, 1995 Do Do Intended for Human Immunodeficiency Virus (HIV-1 and/or HIV-2) Antibody Testing; Revisions to Previous Guidance Interim Definition and Elimination of December 8, 1995 Do Do Lot-by-Lot Release for Well- Characterized Therapeutic Recombinant DNA-Derived and Monoclonal Antibody Biotechnology Products Guidance for Industry in Designing June 24, 1996 Do Do Clinical Programs for Developing Human Drugs, Medical Devices, or Biological Products Intended for the Treatment of Rheumatoid Arthritis; Availability of Draft Guidance; Notice of Public Workshop on Juvenile Rheumatoid Arthritis Draft Public Health Service Guideline September 23, 1996 Do Do on Infectious Disease Issues in Xenotransplantation; Notice The Food and Drug Administration's February 27, 1997 Do Do Development, Issuance, and Use of Guidance Documents Preclearance of Promotional Labeling; March 5, 1997 Do Do Clarification Draft Guidance for Industry: June 18, 1997 Do Do Computerized Systems Used in Clinical Trials; Availability Recommended Methods for Short Ragweed November 1, 1985 Do Do Pollen Extracts Information Relevant to the August 23, 1989 Do Do Manufacture of Acellular Pertussis Vaccine Recommended Methods for Blood Grouping March 1, 1992 Do Do Reagents Evaluation Recommended Methods for Evaluating March 1, 1992 Do Do Potency, Specificity and Reactivity of Anti-Human Globulin Methods of the Allergenic Products October 1, 1993 Do Do Testing Laboratory [[Page 9799]] Guide to Inspections of Blood Banks, September 1, 1994 Do Do Division of Field Investigations, Office of Regional Operations, Office of Regulatory Affairs Guide to Inspections of Infectious June 1, 1996 Do Do Disease Marker Testing Facilities Guide to Inspections of Source Plasma June 1, 1997 Do Do Establishments (Division of Field Investigations, Office of Regional Operations, Office of Regulatory Affairs) Notification Process for Transfusion October 7, 1997 Do Do Related Fatalities and Donation Related Deaths (revised telephone number) Submission Requirements for Requesting October 15, 1997 Do Do Certificates for Exporting Products to Foreign Countries CBER Refusal to File (RTF) Guidance July 12, 1993 Do Do for Product and Establishment License Applications OELPS, Advertising and Promotional August 1, 1994 Do Do Labeling Staff Procedural Guidance Document (Draft) Guidance on Alternatives to Lot October 27, 1994 Do Do Release for Licensed Biological Products Content and Format of Investigational November 1, 1995 Do Do New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products Computer Assisted Product License March 1, 1996 Do Do Application (CAPLA) Guidance Manual FDA Guidance Concerning Demonstration April 26, 1996 Do Do of Comparability of Human Biological Products, Including Therapeutic Biotechnology-Derived Products Guidance for Industry--The Content and May 23, 1996 Do Do Format for Pediatric Use Supplements Guidance on Applications for Products May 24, 1996 Do Do Comprised of Living Autologous Cells Manipulated Ex Vivo and Intended for Structural Repair of Reconstruction Guidance for Industry for the August 15, 1996 Do Do Submission of Chemistry, Manufacturing, and Controls Information for a Therapeutic Recombinant DNA-Derived Product or a Monoclonal Antibody Product for In Vivo Use Draft Guidance for Industry: September 20, 1996 Do Do Manufacture, Processing or Holding of Active Pharmaceutical Ingredients Draft Guidance for Industry; November 4, 1996 Do Do Submitting Application Archival Copies in Electronic Format Draft Guidance for Industry; November 4, 1996 Do Do Electronic Submission of Case Report Forms and Case Report Tabulations Guidance for the Submission of January 10, 1997 Do Do Chemistry, Manufacturing, and Controls Information and Establishment Description for Autologous Somatic Cell Therapy Products Proposed Approach to Regulation of February 28, 1997 Do Do Cellular and Tissue-Based Products Tables 1 and 2 from Proposed Approach March 4, 1997 Do Do to Regulation of Cellular and Tissue- Based Products Guidance for Industry-FDA Approval of March 13, 1997 Do Do New Cancer Treatment Uses for Marketed Drug and Biological Products Guidance for Industry-Providing March 13, 1997 Do Do Clinical Evidence of Effectiveness for Human Drug and Biological Products Guidance for Industry for the April 10, 1997 Do Do Evaluation of Combination Vaccines for Preventable Diseases: Production, Testing and Clinical Studies Guidance for Industry--Changes to an July 24, 1997 Do Do Approved Application: Biological Products Guidance for Industry--Changes to an July 24, 1997 Do Do Approved Application for Specified Biotechnology and Specified Synthetic Biological Products Guidance for Industry--Screening and July 29, 1997 Do Do Testing of Donors of Human Tissue Intended for Transplantation [[Page 9800]] Guidance for Industry--Donor Screening August 15, 1997 Do Do for Antibodies to HTLV-II Guidance for Industry on Testing August 25, 1997 Do Do Limits in Stability Protocols for Standardized Grass Pollen Extracts Guidance for Industry - Postmarketing August 27, 1997 Do Do Adverse Experience Reporting for Human Drug and Licensed Biological Products: Clarification of What to Report Guidance for Industry Efficacy September 1, 1997 Do Do Evaluation of Hemoglobin-and Perfluorocarbon-Based Oxygen Carriers Guidance for Industry--The Sourcing October 7, 1997 Do Do and Processing of Gelatin to Reduce the Potential Risk Posed by Bovine Spongiform Encephalopathy (BSE) in FDA-Regulated Products for Human Use Draft Guidance for Industry--For December 29, 1997 Do Do Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Plasma-Derived Biological Products or Animal Plasma or Serum- Derived Products FDA's Policy Statement Concerning November 25, 1992 Do Do Cooperative Manufacturing Arrangements for Licensed Biologics FDA Guidance Document Concerning Use July 11, 1995 Do Do of Pilot Manufacturing Facilities for the Development and Manufacture of Biological Products; Availability Changes to be Reported for Product and April 6, 1995 Do Do Establishment License Applications; Guidance Advertising and Promotion; Guidance; October 8, 1996 Do Do Notice Interpretative Guidelines of the October 2, 1973 Do Do Source Plasma (Human) Standards Guidelines for Reviewing Amendments to July 20, 1976 Do Do Include Plasmapheresis of Hemophiliacs Package Insert: Immune Serum Globulin March 30, 1978 Do Do (Human) Guidelines for Interpretation of April 12, 1979 Do Do Potency Test Results for All Forms of Adsorbed Diphtheria and Tetanus Toxoids Guidelines for Immunization of Source June 1, 1980 Do Do Plasma (Human) Donors with Blood Substances Collection of Human Leukocytes for January 28, 1981 Do Do Further Manufacturing (Source Leukocytes) Platelet Testing Guidelines--Approval July 1, 1981 Do Do of New Procedures and Equipment Revised Guideline for Adding Heparin August 1, 1981 Do Do to Empty Containers for Collection of Heparinized Source Plasma (Human) Guidelines for Meningococcal July 17, 1985 Do Do Polysaccharide Vaccines Guideline for the Uniform Labeling of August 1, 1985 Do Do Blood and Blood Components Guideline for Submitting Documentation February 1, 1987 Do Do for the Stability of Human Drugs and Biologics Guideline for Submitting Documentation February 1, 1987 Do Do for Packaging for Human Drugs and Biologics Guideline On General Principles of May 1, 1987 Do Do Process Validation Guideline On Sterile Drug Products June 1, 1987 Do Do Produced by Aseptic Processing Guideline On Validation of the Limulus December 1, 1987 Do Do Amebocyte Lysate Test as an End- Product Endotoxin Test for Human and Animal Parenteral Drugs, Biological Products, and Medical Devices Revised Guideline for the Collection October 7, 1988 Do Do of Platelets, Pheresis Draft Guideline for the Design of November 1, 1988 Do Do Clinical Trials for Evaluation of Safety and Efficacy of Allergenic Products for Therapeutic Uses Guidelines for Release of Pneumococcal February 1, 1989 Do Do Vaccine, Polyvalent FDA Regulated Industries for Drug September 1, 1989 Do Do Master Files [[Page 9801]] FDA Regulated Industries for October 26, 1989 Do Do Collection of Blood or Blood Products from Donors With Positive Tests for Infectious Disease Markers (``High Risk'' Donors) Guideline for Determination of January 1, 1990 Do Do Residual Moisture in Dried Biological Products Guideline on the Preparation of March 1, 1991 Do Do Investigational New Drug Products (Human & Animal) Draft Guideline for the Validation of September 28, 1993 Do Do Blood Establishment Computer Systems Guideline for Adverse Experience October 15, 1993 Do Do Reporting for Licensed Biological Products Guideline for Quality Assurance in July 11, 1995 Do Do Blood Establishments To Biologic Product Manufacturers-- May 3, 1991 Do Do controlling materials of bovine or ovine origin To Sponsors of INDs using Retroviral September 20, 1993 Do Do Vectors To Manufacturers: Bovine Derived December 17, 1993 Do Do Materials (BSE) To Blood Establishment Computer March 31, 1994 Do Do Software Manufacturers To Sponsors of INDs for Human May 23, 1994 Do Do Immunoglobulin Products To Manufacturers of Licensed Anti-HIV May 26, 1994 Do Do Test Kits To Manufacturers of Immune Globulin December 27, 1994 Products: Testing for Hepatitis C Virus RNA Immunoglobulin To Blood Establishment Computer February 10, 1995 Do Do Software Manufacturers To Manufacturers of Intramuscular March 3, 1995 Do Do Immune Globulin Products: HCV RNA testing by PCR To Manufacturers of Intramuscular March 13, 1995 Do Do Immune Globulin Products: Additional information regarding HCV RNA testing by PCR To Health Professionals: March 14, 1995 Do Do implementation of testing for HCV RNA by PCR for immune globulin products for intramuscular administration Dear Colleague: Regarding Reverse January 4, 1996 Do Do Transcriptase Activity in Viral Vaccines Produced in Chicken Cells To Manufacturers of FDA--Regulated May 9, 1996 Do Do Drug/Biological/Device Products, Bovine Spongiform Encephalopathy (BSE) To Manufacturers: Implementation of June 13, 1996 Do Do testing for Hepatitis C virus RNA by polymerase chain reaction (PCR) of intramuscular immune globulin preparations To Manufacturers: HIV-1 Group O July 31, 1996 Do Do To All Plasma Derivative Manufacturers October 7, 1996 Do Do and to ABRA: Warning Statement for Plasma Derivative Product Labeling To Biologic Product Manufacturers: December 3, 1996 Do Do Revised procedures for internal labeling review number assignment To In Vitro Diagnostic Reagent December 6, 1985 Do Do Manufacturers: Guidance On the Labeling of Human Blood Derived In Vitro Diagnostic Devices In Regard to Labeling for HTLV-III/LAV Antibody Testing PTC in the Manufacture of In Vitro June 20, 1983 Do Do Monoclonal Antibody Products Subject to Licensure Draft PTC in the Production and July 28, 1983 Do Do Testing of Interferon Intended for Investigational Use in Humans (Interferon Test Procedures) Draft PTC in the Production and April 10, 1985 Do Do Testing of New Drugs and Biologicals Produced by Recombinant DNA Technology Draft PTC in the Manufacture and August 8, 1989 Do Do Clinical Evaluation of In Vitro Tests to Detect Antibodies to Human Immunodeficiency Virus Type 1 (1989) PTC in the Collection, Processing and August 22, 1989 Do Do Testing of Ex Vivo Activated Mononuclear Leukocytes for Administration to Humans [[Page 9802]] Cytokine and Growth Factor Pre-Pivotal April 2, 1990 Do Do Trial Information Package PTC in the Safety Evaluation of August 21, 1990 Do Do Hemoglobin-Based Oxygen Carriers Draft PTC in Human Somatic Cell August 27, 1991 Do Do Therapy and Gene Therapy PTC in the Design and Implementation March 1, 1992 Do Do of Field Trials for Blood Grouping Reagents and Anti-Human Globulin PTC in the Manufacture of In Vitro March 1, 1992 Do Do Monoclonal Antibody Products for Further Manufacturing into Blood Grouping Reagent and Anti-Human Globulin Supplement to the PTC in the April 6, 1992 Do Do Production and Testing of New Drugs and Biologicals Produced by Recombinant DNA Technology: Nucleic Acid Characterization and Genetic Stability Draft PTC in the Characterization of July 12, 1993 Do Do Cell Lines Used to Produce Biologicals PTC in the Manufacture and Testing of August 22, 1995 Do Do Therapeutic Products for Human Use Derived from Transgenic Animals Draft Addendum to the PTC in Human January 2, 1996 Do Do Somatic Cell and Gene Therapy PTC on Plasmid DNA Vaccines for December 22, 1996 Do Do Preventive Infectious Disease Indications PTC in the Manufacture and Testing of February 28, 1997 Do Do Monoclonal Antibody Products for Human Use Reviewer Guidance, Computer Software April 26, 1995 FDA Personnel Do Informed Consent for Plasmapheresis/ October 1, 1995 Do Do Immunization Draft Reviewers' Guide: Changes in October 1, 1995 Do Do Personnel Disease Associated Antibody Collection October 1, 1995 Do Do Program Centerwide Policy on Issuance of and August 20, 1996 Do Do Response to Clinical Hold Letters for Investigational New Drug Applications Reviewer Guidance for a Premarket January 13, 1997 Do Do Notification Submission for Blood Establishment Computer Software ---------------------------------------------------------------------------------------------------------------- III. Guidance Documents Issued by the Center for Devices and Radiological Health (CDRH) ---------------------------------------------------------------------------------------------------------------- How to Obtain a Hard Copy of Grouped by Intended the Document (Name and Name of Document Date of Issuance User or Regulatory Address, Phone, FAX, E-mail, Activity or Internet) ---------------------------------------------------------------------------------------------------------------- MDR Reporting Guidance For Breast August 7, 1996 Office of Division of Small Implants--E1996002 Surveillance and Manufacturers Assistance, 1- Biometrics (OSB) 800-638-2041 or 301-827-0111 or (Fax) Facts on Demand at 1-800-899-0381 or Internet at http://www.fda.gov/cdrh Instructions for Completing Form 3417: March 31, 1987 OSB Do Medical Device Reporting Baseline Report [MDR] MDR Guidance Document No. 1--IOL-- August 7, 1996 Do Do E1996004 MDR Guidance Document No. 3-- August 9, 1996 Do Do Needlestick & Blood Exposure-- E1996003 Statistical Guidance for Clinical January 1, 1996 Do Do Trials of Non Diagnostic Medical Devices (Replaces Clinical Study Guidance) Medical Device Reporting: An Overview April 1996 Do Do Instructions for Completing FDA Form December 15, 1995 Do Do 3500A with Coding Manual for Form 3500A (MEDWATCH) MEDWATCH FDA Form 3500A for Use by June 1, 1993 Do Do User Facilities, Distributors, and Manufacturers for Mandatory Reporting [[Page 9803]] Amendment to Guidance on Discretionary March 30, 1994 Do Do Postmarket Surveillance on Pacemaker Leads Proposed Draft Guidance to Sponsors October 7, 1994 Do Do Regarding Required Postmarket Surveillance Studies of Plasma-- Sprayed Porous-Coated Hip Prostheses Required Postmarket Surveillance July 31, 1997 Do Do Section 522(a) Initial Device Categories Revised MDR Guidance Document: Remedial Action July 30, 1996 Do Do Exemption--E1996001 MDR Internet List Server (listserv) August 29, 1996 Do Do Instruction sheet Semi-Annual Report, Form 3419 (MDR) September 24, 1996 Do Do Variance from Manufacturer Report July 16, 1996 Do Do Number Format (MDR letter) Guidance to Manufacturers on the November 8, 1991 Do Do Development of Required Postmarket Surveillance Study Protocols Under Section 522(a)(1) of the Federal Food, Drug, and Cosmetic Act Medical Device Reporting for April 1996 Do Do Distributors Medical Device Reporting for March 1997 Do Do Manufacturers Guidance to Sponsors on the June 9, 1993 Do Do Development of a Discretionary Postmarket Surveillance Study for Permanent Implantable Cardiac Pacemaker Electrodes (Leads) Instructions for Completing Semi- September 24, 1996 Do Do Annual Report, Form 3419 (MDR) Variance from Manufacturer Report August 12, 1996 Do Do Number Format Variance from Manufacturer Report July 16, 1996 Do Do Number Format Statistical Aspects of Submissions to June 1, 1984 Do Do FDA: A Medical Device Perspective (also includes as Appendix the article Observed Uses and Abuses of Statistical Procedures in Medical Device Investigational Device Exemptions June 1, 1996 Office of Health and Do [IDE] Manual (FDA 96-4159)/DSMA Industry Programs (OHIP), Division of Small Manufacturer's Assistance (DSMA) Additional Guidance for Testing September 1, 1993 Do Do Immunity to Radiated Electromagnetic Fields--Infant Apnea Monitor Standard Premarket Approval (PMA) Manual (FDA April 1, 1993 Do Do 93-4214) Comparison Chart: 1996 Quality System Do Do Reg vs. 1978 Good Manufacturing Practices Reg vs. ANSI/ISO/ASQC Q9001 and ISO/DI 13485:1996 (include 126) Obtaining CDRH Guidance Documents October 21, 1997 Do Do Regulatory Requirements for Devices August 1, 1987 Do Do for the Handicapped (FDA 87-4221) Small Business Guide to FDA (FDA 96- January 1, 1996 Do Do 1092) MDR Documents Access Information May 10, 1996 Do Do MDR Documents Access Information for February 29, 1996 Do Do CDRH Electronic Docket (ED) MDR Documents Access Information for February 29, 1996 Do Do CDRH Facts-On-Demand (FOD) MDR Documents Access Information for May 8, 1996 Do Do Industry Organizations MDR Documents Access Information for May 10, 1996 Do Do National Technical Information Service (NTIS) MDR Documents Access Information for February 29, 1996 Do Do World Wide Web (WWW) Addendum to What a Mammography July 31, 1996 OHIP/Division of MQSA Facility Should do to Prepare for an Mammography Quality MQSA Inspection and Radiation Programs (DMQRP)/ Mammography Quality Standards Act (MQSA) Handbook of Selected Tissue Doses for September 1, 1995 Do Do Fluoroscopic and Cineangiographic Examination of the Coronary Arteries (in SI Units) FDA 95-8289, (Units of milliray (mmmGy) tissue Policy Statements in Question and October 7, 1997 Do Do Answer Format [[Page 9804]] What a Mammography Facility Should Do June 30, 1995 Do Do to Prepare for an MQSA Inspection Classification Names for Medical March 1, 1995 Do Do Devices and In Vitro Diagnostic Products (FDA Pub No. 95-4246) Import of Medical Devices--A Workshop March 1, 1993 Do Do Manual (FDA 93-4228) Labeling--Regulatory Requirements for September 1, 1989 Do Do Medical Devices (FDA 89-4203) List of Current CDRH Addresses for July 30, 1996 Do Do Report Submission and Ordering of CDRH Forms Premarket Notification: 510(k)-- August 1, 1995 Do Do Regulatory Requirements for Medical Devices (FDA 95-4158) Procedures for Laboratory Compliance May 1, 1986 Do Do Testing of Television Receivers--part of TV Packet U.S. Food and Drug Administration May 1, 1996 Do Do Regulation of Medical Devices-- Background Information for Foreign Officials Instructions for Completion of Medical July 1, 1997 Do Do Device Registration and Listing Forms FDA 2891, 2891a and 2892 In Vitro Diagnostic Devices: Guidance January 1, 1997 Do Do for the Preparation of 510(k) Submissions (supersedes FDA 87-4224) An Introduction to Medical Device January 1, 1992 Do Do Regulations (FDA 92-4222) Do It By Design--An Introduction to December 1, 1996 OHIP/Division of Do Human Factors in Medical Devices Device User Programs and Systems Analysis (DDUPSA) Good Guidance Practices Standard October 17, 1997 Do ............................. Operating Procedures Manual for the Development and Use of Guidance Documents in CDRH Human Factors Principles for Medical September 1, 1993 Do Do Device Labeling Medical Device Reporting for User April 1996 Do Do Facilities Write it Right August 1, 1993 Do Do Human Factors Points to Consider for January 17, 1997 Do Do IDE Devices Medical Devices and EMI: The FDA January 1, 1995 Office of Compliance Do Perspective Enforcement Policy; Recalls (Including June 16, 1978 Do Do Product Corrections)--Guidelines on Policy; Procedures; and Industry Responsibilities Sec. 300.600 Commercial Distribution September 24, 1987 Do Do with Regard to Premarket Notification [Section 510(k)] [CPG 7124.19] Procedures for Obtaining FDA Approval January 13, 1995 Do to Export Unapproved Medical Devices The FDA Export Reform and Enhancement October 1, 1996 Do Do Act of 1996/Export Certification FDA Regulatory Procedures Manual May 23, 1991 Do Do Chapter 8-10 Warning Letters A Pocket Guide to Device GMP November 1, 1991 Do Do Inspections--Inspections of Medical Device Manufacturers and GMP Regulation Requirements Commercial Distribution/Exhibit Letter April 10, 1992 Do Do (Use instead of Hile letter) (Display) Diagnostic Ultrasound Guidance Update January 30, 1987 Office of Compliance Do (OC)/Division of Enforcement I (DOE I) Doppler Ultrasound Guidance Update March 7, 1986 Do Do Manufacturers/Assemblers of Diagnostic October 13, 1993 Do Do X-ray Systems: Enforcement Policy for Positive-Beam Limitation (PBL) Requirements in 21 CFR 1020.31(g) A Guide for the Submission of March 1, 1996 Do Do Abbreviated Radiation Safety Reports on Cephalometric X-Ray Devices: Defined as Dental Units with an Attachment for Mandible Work that Holds a A Guide for the Submission of March 1, 1996 Do Do Abbreviated Radiation Safety Reports on Image Receptor Support Devices for Mammographic X-Ray Systems [[Page 9805]] A Guide for the Submission of an March 1, 1996 Do Abbreviated Radiation Safety Report on X-Ray Tables, Cradles, Film Changers or Cassette Holders Intended for Diagnostic Use All Diagnostic Ultrasound February 24, 1986 Do Do Manufacturers and Importers-Exemption from Reporting under 21 CFR 1002 Clarification of Radiation Control March 1, 1989 Do Do Regulations for Diagnostic X-Ray Equipment (FDA 89-8221) Guide for the Submission of Initial January 1, 1982 Do Do Reports on Diagnostic X-Ray Systems and their Major Components Letter to Medical Device Industry on May 17, 1993 Do Do Endoscopy and Laparoscopy Accessories (Galdi) Medical Device Tracking: Questions and August 26, 1993 Do Do Answers Based on the Final Rule Guideline for the Manufacture of In January 10, 1994 Do Do Vitro Diagnostic Products Retention of Records Required by 21 August 24, 1981 Do Do CFR 1002 Letter to Manufacturers/Repackers April 22, 1994 OC/Division of Do Using Cotton Enforcement II (DOE II) Condoms: Inspection and Sampling at April 8, 1987 Do Do Domestic Manufacturers and of all Repackers; Sampling from all Importers (Damaska Memo to Field on 4/ 8/87) Hazards of Volume Ventilators and September 15, 1993 Do Do Heated Humidifiers Compliance Guide for Laser Products September 1, 1985 Do Do (FDA 86-8260) Dental Handpiece Sterilization (Dear September 28, 1992 Do Do Doctor Letter) Ethylene Oxide; Ethylene Chlorohydrin; June 23, 1978 Do Do and Ethylene Glycol; Proposed Maximum Residue Limits and Maximum Levels of Exposure GLOVES Information About Medical September 1, 1993 Do Do Gloves Letter--Manufacturers, Distributors February 23, 1994 Do Do and Importers of Condom Products [included in Condom Packet #398] Letter--Manufacturers, Importers, and February 13, 1989 Do Do Repackagers of Condoms for Contraception or Sexually-Transmitted Disease Prevention (Holt) [included in Condom Packet #398] Pesticide Regulation Notice 94-4: June 30, 1994 Do Do Interim Measures for the Registration of Antimicrobial Products/Liquid Chemical Germicides with Medical Device Use Claims Under the Regulatory Requirements for Medical September 1, 1996 Do Do Gloves--A Workshop Manual FDA Publication No. 96-4257 Standard Specification for Rubber October 28, 1983 Do Do Contraceptives (Condoms) [included in Condom Packet #398] Sterilization: Questions and Answers January 1, 1985 Do Do from FDA, from Medical Device and Diagnostic Industry for January, 1985, page 132 All U.S. Condom Manufacturers, April 7, 1987 Do Do Importers and Repackagers Letter to Ophthalmologists about June 27, 1997 Do Do Lasers for Refractive Surgery Manufacturers and Initial Distributors May 23, 1996 Do Do of Hemodialyzers Manufacturers and Users of Lasers for October 10, 1996 Do Do Refractive Surgery Manufacturers of Laparoscopic Trocars, August 23, 1996 Do Do used for Abdominal Access Prospective Manufacturers of Barrier October 31, 1996 Do Do Devices used during Oral Sex for STD Protection Impact Resistant Lenses: Questions and September 1, 1987 Do Do Answers (FDA 87-4002) [see shelf--# 460] Letter to Industry, Powered Wheelchair May 10, 1993 Do Do Manufacturers from RMJohnson [[Page 9806]] Manufacturers and Initial Distributors February 3, 1994 Do Do of Sharps Containers and Destroyers Used by Health Care Professionals Guide for Preparing Product Reports September 1, 1995 Do Do for Lasers and Products Containing Lasers Letter--Condom Manufacturers and April 5, 1994 Do Do Distributors Suggested State Regulations for January 1, 1982 OC/Division of Do Control of Radiation--Volume II Enforcement III (DOE Nonionizing Radiation--Lasers (FDA III) Pub No. 83-8220) Quality Assurance Guidelines for February 1, 1991 Do Do Hemodialysis Devices Quality Control Guide for Sunlamp March 1, 1988 Do Do Products (FDA 88-8234) Quality Control Practices for May 1, 1980 Do Do Compliance with the Federal Mercury Vapor Lamp Performance Standard Reporting and Compliance Guide for October 1, 1995 Do Do Television Products including Product Report, Supplemental Report, Radiation Safety Abbreviated Report, Annual Report, Informational Guidance Policy on Lamp Compatibility September 2, 1986 Do Do (sunlamps) Policy on Maximum Timer Interval and August 21, 1986 Do Do Exposure Schedule for Sunlamp Products Policy on Warning Label Required on June 25, 1985 Do Do Sunlamp Products Imports Radiation-Producing Electronic November 1, 1988 Do Do Products (FDA 89-8008) Information Requirements for Cookbooks October 31, 1988 Do Do and User and Service Manuals Keeping Up With the Microwave March 1, 1990 Do Do Revolution (FDA Pub No. 91-4160) Laser Light Show Safety--Who's May 1, 1986 Do Do Responsibility (FDA 86-8262) Letter to All Foreign Manufacturers May 28, 1981 Do Do and Importers of Electronic Products for Which Applicable FDA Performance Standards Exist General Principles of Software June 9, 1997 Do Do Validation; Draft Guidance Reporting Guide for Laser Light Shows September 1, 1995 Do Do and Displays (21 CFR 1002) (FDA 88- 8140) Reporting Guide for Product Reports on September 1, 1995 Do Do High Intensity Mercury Vapor Discharge Lamps (21 CFR 1002) Revised Guide for Preparing Annual September 1, 1995 Do Do Reports on Radiation Safety Testing of Laser and Laser Light Show Products (replaces FDA 82-8127) Safety of Electrically Powered September 18, 1996 Do Do Products: Letter To Medical Device and Electronic Product Manufacturers From Lillian Gill & BHB correction memo Unsafe Patient Lead Wires and Cables September 3, 1993 Do Do Design Control Guidance for Medical March 11, 1997 Do Do Device Manufacturers Final Design Control Inspectional March 1, 1997 Do Do Strategy Guide for Preparing Abbreviated September 1, 1996 Do Do Reports of Microwave and RF Emitting Electronic Products Intended for Medical Use Guide for Preparing Annual Reports for September 1, 1996 Do Do Ultrasonic Therapy Products Guide for Preparing Product Reports September 1, 1996 Do Do for Medical Ultrasound Products Guide for Preparing Product Reports August 1, 1996 Do Do for Ultrasonic Therapy Products (physical therapy only) Application for a Variance from 21 CFR March 1, 1987 Do Do 1040.11(c) for a Laser Light Show, Display, or Device Letter to Trade Association: ReUse of December 27, 1995 Do Do Single-use or Disposable Medical Devices Letter: Changes in Regulations October 27, 1995 Do Do Concerning Records and Reports on Radiation-Emitting Electronic Products [[Page 9807]] Medical Device Electromagnetic Do Do Interference Issues, Problem Reports, Standards, and Recommendations Computerized Devices/Processes May 1, 1992 Do Do Guidance--Application of the Medical Device GMP to Computerized Devices and Manufacturing Processes Keeping Medical Devices Safe from July 1, 1995 Do Do Electromagnetic Interference Latex Labeling Letter (Johnson) Do Do Guide for Preparing Annual Reports on September 1, 1995 Do Do Radiation Safety Testing of Mercury Vapor Lamps (replaces FDA 82-8127) Guide for Preparing Annual Reports on September 1, 1995 Do Do Radiation Safety Testing of Sunlamps and Sunlamp Products (replaces FDA 82- 8127) Guide for Preparing Product Reports on September 1, 1995 Do Do Sunlamps and Sunlamp Products (21 CFR 1002) Abbreviated Reports on Radiation August 1, 1995 Do Do Safety for Microwave Products (Other Than Microwave Ovens)--e.g., Microwave Heating, Microwave Diathermy, RF Sealers, Induction, Dielectric Abbreviated Reports on Radiation August 1, 1995 Do Do Safety of Non-Medical Ultrasonic Products Guidance for the Submission of Cabinet February 1, 1975 Do Do X-Ray System Reports Pursuant to 21 CFR 1020.40 Guide for Preparing Annual Reports on October 1, 1987 Do Do Radiation Safety Testing of Electronic Products (General) Guide for Preparing Initial Reports April 1, 1989 Do Do and Model Change Reports on Medical Ultraviolet (UV) Lamps and Products Containing Such Lamps (21 CFR 1002.10 and 1002.12) Guide for Preparing Reports on March 1, 1985 Do Do Radiation Safety of Microwave Ovens Guide for Submission of Information on April 1, 1971 Do Do Accelerators Intended to Emit X- Radiation Required Pursuant to 21 CFR 1002.10 Guide for Submission of Information on April 30, 1974 Do Do Analytical X-Ray Equipment Required Pursuant to 21 CFR 1002.10 Guide for Submission of Information on September 1, 1980 Do Do Industrial Radiofrequency Dielectric Heater and Sealer Equipment Pursuant to 21 CFR 1002.10 and 1002.12 (FDA 81- 8137) Guide for Submission of Information on March 1, 1973 Do Do Industrial X-Ray Equipment Required Pursuant to 21 CFR 1002.10 Guide for the Filing of Annual Reports July 1, 1980 Do Do for X-Ray Components and Systems Guide for the Submission of Initial September 1, 1984 OC/DOE I and III Do Reports on Computed Tomography X-Ray Systems Additional Information for Initial April 9, 1993 Do Do Reports All Diagnostic Ultrasound February 24, 1986 Do Do Manufacturers and Importers Exemption from Reporting under 21 CFR 1002 Guideline for Preparing Notices of November 1, 1985 OC/Bioresearch Do Availability of Investigational Monitoring (BIMO) Medical Devices Recommended Test Methods Infant Apnea September 1, 1993 Office of Standards Do Monitor Standard and Technology (OST) Draft Document--A Primer on Medical February 7, 1997 Do Do Device Interactions with Magnetic Resonance Imaging Systems Letter to Medical Device Manufacturer February 14, 1995 CDRH, Office of the Do on Pentium Processors Director (OD) ``Real-Time'' Review Program for April 22, 1997 Office of Device Do Premarket Approval Application (PMA) Evaluation (ODE) Supplements A New 510(k) Paradigm--Alternate June 13, 1997 Do Do Approaches to Demonstrating Substantial Equivalence in Premarket Notifications Freedom of Information/510(K) Process May 15, 1997 Do Do Changes [[Page 9808]] Reexamination of the Evaluation May 19, 1997 Do Do Process for Liquid Chemical Sterilant and High Level Disinfectants Center for Devices and Radiological June 30, 1993 Do Do Health's Investigational Device Exemption (IDE) Refuse to Accept Policy Center for Devices and Radiological June 30, 1993 Do Do Health's Premarket Notification [510(k)] Refuse to Accept Policy-- (updated Checklist 3/14/1995) 4-of-A-Kind PMA's October 1, 1991 Do Do Application of the Device Good December 1, 1983 Do Do Manufacturing Practice (GMP) Regulation to the Manufacture of Sterile Devices Biotechnology and FDA Regulation of January 1, 1986 Do Do Hybridoma In-Vitro Diagnostic Products: List of Current Devices and Guidelines for Manufacturers CDRH's 510(k)/IDE/PMA Refuse to Accept/ June 30, 1993 Do Do Accept/File Policies (see #D94-1, #K94-1, & #P94-1) Classified Convenience Kits April 30, 1993 Do Do Color Additive Petitions (p. II-19 of June 1, 1987 Do Do PMA Manual) Color Additive Status List (Inspection February 1, 1989 Do Do Operations Manual) Color Additives for Medical Devices November 15, 1995 Do Do (Snesko) Deciding When to Submit a 510(k) for a January 10, 1997 Do Do Change to an Existing Device [see CDRH F-O-D #1935] Device Specific Guidance Documents May 11, 1993 Do Do (List) FDA Clinical Investigator Information May 1, 1989 Do Do Sheets FDA Guide for Validation of Biological January 1, 1986 Do Do Indicator Incubation Time (Source: Sterilization Committee; through Virginia Ross; HFZ-332) FDA Policy For The Regulation Of November 13, 1989 Do Do Computer Products (DRAFT) [See 2099] Format for IDE Progress Reports Do Do Guidance for Preparation of PMA August 1, 1992 Do Do Manufacturing Information Guide for Establishing and Maintaining March 1, 1988 Do Do a Calibration Constancy Intercomparison System for Microwave Oven Compliance Survey Instruments (FDA 88-8264) Guideline for the Monitoring of January 1, 1988 ODE Do Clinical Investigations Guideline on General Principles of May 1, 1987 Do Do Process Validation Guideline on Sterile Drug Products June 1, 1987 Do Do Produced by Aseptic Processing Guideline on Validation of the Limulus December 1, 1987 Do Do Amebocyte Lysate (LAL) Test as an End- Product Endotoxin Test Indications for Use Statement January 2, 1996 Do Do Industry Representatives on Scientific March 27, 1987 Do Do Panels Labeling Reusable Medical Devices for April 1, 1996 Do Do Reprocessing in Health Care Facilities: FDA Reviewer Guidance (see 1198) Limulus Amebocute Lysate; Reduction of October 23, 1987 Do Do Samples for Testing Master Files Part III; Guidance on June 1, 1987 Do Do Scientific and Technical Information Memorandum: Electromagnetic June 13, 1995 Do Do Compatibility for Medical Devices: Issues and Solutions Methods for Conducting Recall June 16, 1978 Do Do Effectiveness Checks Necessary Information for Diagnostic November 24, 1987 Do Do Ultrasound 510(k) (Draft) Perspectives on Clinical Studies for Do Do Medical Device Submissions (Statistical) PMA Review Schedule March 31, 1988 Do Do PMA Review Statistical Checklist Do Do Points to Consider in the June 1, 1984 Do Do Characterization of Cell Lines Used to Produce Biological Products (from John C. Petricciani, M.D.) Preamendment Class III Devices March 11, 1992 Do Do [[Page 9809]] Premarket Notification [510(k)] Status March 7, 1994 Do Do Request Form, revised Premarket Submission Coversheet, January 19, 1995 Do Do Instructions, and Survey Preproduction Quality Assurance September 1, 1989 Do Do Planning: Recommendations for Medical Device Manufacturers (FDA 90-4236) Proposal for Establishing Mechanisms June 30, 1993 Do Do for Setting Review Priorities Using Risk Assessment and Allocating Review Resources (include with 926-930) Questions and Answers for the FDA September 3, 1996 Do Do Reviewer Guidance: Labeling Reusable Medical Devices for Reprocessing in Health Care Facilities Reviewer Guidance for Computer August 29, 1991 Do Do Controlled Medical Devices Undergoing 510(k) Review Shelf Life of Medical Devices March 1, 1991 Do Do Substantial Equivalence (SE) Decision January 1, 1990 Do Do Making Documentation ATTACHED: ``SE'' Decision Making Process (Detailed) i.e. the decision making tree Suggested Content for Original IDE February 27, 1996 Do Do Application Cover Letter--Version 4 Suggestions for Submitting a Premarket April 1, 1993 Do Do Approval (PMA) Application Threshold Assessment of the Impact of January 1, 1990 Do Do Requirements for Submission of PMA's for 31 Medical Devices Marketed Prior to May 28, 1976 Viable Bacteriophage in Co2 Laser Do Do Plume: Aerodynamic Size Distribution Drugs of Abuse Screening Test Devices July 21, 1987 Do Do Letter--Vascular Graft Industry November 22, 1995 Do Do (Philip Phillips) Letter to Industry, Powered Wheelchair/ May 26, 1994 Do Do Scooter or Accessory/Component Manufacturer from Susan Alpert, Ph.D.,M.D. Preamendments Class III Strategy; April 19, 1994 Do Do SXAlpert Draft Guidance to Firms on Biliary August 2, 1990 ODE/Division of Do Lithotripsy Studies Reproductive, Abdominal, ENT, and Radiological Devices (DRAERD) Letter: Notice to Manufacturers of September 25, 1997 Do Do Bone Mineral Densitometers 510(k) Checklist for Sterile September 19, 1994 Do Do Lubricating Jelly Used With Transurethral Surgical Instruments CDRH Interim Regulatory Policy for September 10, 1997 Do Do External Penile Rigidity Devices Checklist for Mechanical Lithotripters November 1, 1994 Do Do and Stone Dislodgers used in Gastroenterology and Urology Draft--510(k) Checklist for November 23, 1994 Do Do Conditioned Response Enuresis Alarms Draft 510(k) Checklist for Condom February 23, 1995 Do Do Catheters Draft 510(k) Checklist for Endoscopic August 16, 1995 Do Do Electrosurgical Unit (ESU) and Accessories Used in Gastroenterology and Urology Draft 510(k) Checklist for Endoscopic June 22, 1995 Do Do Light Sources Used in Gastroenterology and Urology Draft 510(k) Checklist for Non- June 6, 1995 Do Do Implanted Electrical Stimulators Used for the Treatment of Urinary Incontinence Draft 510(k) Checklist for Urological August 1, 1995 Do Do Irrigation System and Tubing Set Draft Guidance for Clinical November 11, 1994 Do Do Investigations of Devices Used for the Treatment of Benign Prostatic Hyperplasia (BPH) Draft Guidance for Information on February 5, 1992 Do Do Clinical Safety and Effectiveness Data for Extracorporeal Shock Wave Lithotripsy of Upper Urinary Tract (Renal Pelvis, Renal) Draft Guidance for Preclinical and November 29, 1995 Do Do Clinical Investigations of Urethral Bulking Agents Used in the Treatment of Urinary Incontinence [[Page 9810]] Draft Guidance for Preparation of PMA March 16, 1993 Do Do Applications for Penile Inflatable Implants Draft Guidance for Preparation of PMA March 16, 1993 Do Do Applications for Testicular Prostheses Draft Guidance for Preparation of PMA May 1, 1995 Do Do Applications for the Implanted Mechanical/Hydraulic Urinary Continence Device (Artificial Urinary Sphincter) Draft Guidance for the Clinical November 2, 1995 Do Do Investigation of Urethral Stents Draft Guidance for the Content of March 17, 1995 Do Do Premarket Notifications for Endoscopes used in Gastroenterology and Urology Draft Guidance for the Content of May 30, 1995 Do Do Premarket Notifications for Penile Rigidity Implants Draft Guidance for the Content of January 24, 1992 Do Do Premarket Notifications for Urological Balloon Dilatation Catheters Draft Guidance Outline--Points to November 30, 1993 Do Do Consider for Clinical Studies for Vasovasostomy Devices Guidance for the Content of Premarket February 10, 1993 Do Do Notifications for Biopsy Devices Used in Gastroenterology and Urology Guidance for the Content of Premarket September 12, 1994 Do Do Notifications for Conventional and Antimicrobial Foley Catheters Guidance for the Content of Premarket February 10, 1993 Do Do Notifications for Ureteral Stents Guidance for the Content of Premarket June 7, 1994 Do Do Notifications for Urine Drainage Bags Guidance for the Content of Premarket July 29, 1994 Do Do Notifications for Urodynamic/ Uroflowmetry Systems Guidance to Manufacturers on the Do Do Development of Required Postapproval Epidemiologic Study Protocols for Testicular Implants 510(k) Guide for Measuring and December 1, 1985 Do Do Reporting Acoustic Output of Diagnostic Ultrasound Medical Devices Draft Guidance for Review of Bone November 9, 1992 Do Do Densitometer 510(k) Submissions Draft MRI Guidance Update for dB/dt October 11, 1995 Do Do [update, include with 8/2/88 document] Guidance for Magnetic Resonance September 29, 1997 Do Do Diagnostic Devices--Criteria for Significant Risk Investigations Guidance for the Comment and Review of August 1, 1993 Do Do 510(k) Notifications for Picture Archiving and Communications Systems (PACS) and Related Devices [See 2099] Guidance for the Submission of 510(k)s June 1, 1997 Do Do for Solid State X-Ray Imaging Devices Information for Manufacturers Seeking April 11, 1997 Do Do Marketing Clearance of Diagnostic Ultrasound Systems and Transducers Information for Manufacturers Seeking June 19, 1996 Do Do Marketing Clearance of Digital Mammography Systems Reviewer Guidance for Automatic X-Ray February 1, 1990 Do Do Film Processor 510(k) Simplified 510(k) procedures for 1994 Do Do certain radiology devices:3 letters 12/21/93; 1/31/94 and 3/31/94 ORDB 510(k) Sterility Review Guidance July 3, 1997 Do Do Condom Packet: 4/13/94 RJRivera April 13, 1994 Do Do Letter, Condom Guidance & 7 Tabs, General Guidance for Modifying Condom Labeling to Include Shelf Life Draft Guidance for the Content of July 29, 1991 Do Do Premarket Notifications for Loop and Rollerball Electrodes for GYN Electrosurgical Excisions Draft Guidance for the Content of May 25, 1995 Do Do Premarket Notifications for Menstrual Tampons Draft Thermal Endometrial Ablation March 14, 1996 Do Do Devices (Submission Guidance for an IDE) Guidance (``Guidelines'') for March 8, 1977 Do Do Evaluation of Fetal Clip Electrode [[Page 9811]] Guidance (``Guidelines'') for May 10, 1978 Do Do Evaluation of Hysteroscopic Sterilization Devices Guidance (``Guidelines'') for Do Do Evaluation of Laparoscopic Bipolar and Thermal Coagulators (and Accessories) Guidance (``Guidelines'') for November 22, 1977 Do Do Evaluation of Tubal Occlusion Devices Guidelines for Evaluation of Non-Drug September 28, 1976 Do Do IUD's Hysteroscopes and Gynecology March 27, 1996 Do Do Laparoscopes--Submission Guidance for a 510(k)--includes 00192 Hysteroscopes and Laparoscopic August 1, 1995 Do Do Insufflators: Submission Guidance for a 510(k) In-vivo Devices for the Detection of June 14, 1997 Do Do Cervical Cancer and its Precursors: Submission Guidance for an IDE Draft Document Intrapartum Continuous Monitors for June 14, 1997 Do Do Fetal Oxygen Saturation and Fetal pH; Submission Guidance for a PMA; Draft Document Premarket Testing Guidelines for November 20, 1992 Do Do Falloposcopes 510(k) Diagnostic Ultrasound Guidance4/ February 1993 Do Do 91 Use of Medical Index in Place of Spatial Peak Intensity in Determining Substantial Equival for Diagnostic Ultrasound Equip/Access/Rel Meas. Dev Premarket Testing Guidelines for April 4, 1990 Do Do Female Barrier Contraceptive Devices also intended to prevent sexually transmitted diseases Premarket Testing Guidelines for Home March 31, 1993 Do Do Uterine Activity Monitors Testing guidance for Male Condoms Made June 29, 1995 Do Do from New Material (Non-Latex) Information for a Latex Condom 510K March 1994 Do Do Subm. for Obstetrics-Gynecology Branch (draft) Guidance for Content and Review of a October 11, 1995 Do Do Magnetic Resonance Diagnostic Device 510(k) Applic. Draft Guidance for Hemodialyzer Reuse October 6, 1995 Do Do Labeling Draft Guidance for the Content of May 30, 1997 Do Do Premarket Notifications for Water Purification Components and Systems for Hemodialysis Guidelines for Premarket Testing of March 1, 1982 Do Do New Conventional Hemodialyzers, High Permeability Hemodialyzers, and Hemofilters Draft of Suggested Information for January 1, 1991 Do Do Reporting Extracorporeal Shock Wave Lithotripsy Device Shock Wave Measurements Draft Guidance to Hearing Aid August 5, 1994 Do Do Manufacturers for Substantiation of Claims Guidance for Submission of a 510(k) April 1, 1991 Do Do Premarket Notification for an Air Conduction Hearing Aid Guidance For The Arrangement and May 1, 1990 Do Do Content of a Premarket Approval (PMA) Application For A Cochlear Implant in Children Ages 2 through to 17 Years Guidance for the Content of Premarket October 21, 1996 Do Do Notification for Disposable, Sterile, Ear, Nose and Throat Endoscope Sheaths with Protective Barrier Claims Guideline for the Arrangement and May 1, 1990 Do Do Content of a Premarket Approval (PMA) Application for a Cochlear Implant in Adults at Least 18 Years of Age Guidance for the Technical Content of April 1, 1990 Do Do a Premarket Approval (PMA) Application for an Endolymphatic Shunt Tube with Valve Amendment 1: Draft Premarket June 28, 1994 ODE/Division of Do Notification [510(k)] Guidance Opthalmics Devices Document for Class II Daily Wear (DOD) Contact Lenses Certification Statement for the Impact .................. Do Do Resistance Test Draft Premarket Notification 510(k) May 1, 1997 Do Do Guidance for Contact Lens Care Products [[Page 9812]] Eye Valve Implant (and all glaucoma November 16, 1995 Do Do drainage devices) manufacturers letter from NCBrogdon FDA Public Health Advisory: Retinal October 16, 1995 Do Do Photic Injuries from Operating Microscopes During Cataract Surgery New FDA Recommendations & Results of May 30, 1989 Do Do Contact Lens Study (7 day letter) Sunglass Letter including 510(k) October 8, 1996 Do Do format Sunglass Package February 3, 1995 Do Do Third Party Review Guidance for January 31, 1997 Do Do Aspiration and Cutting Device Premarket Notification (510(k)) Third Party Review Guidance for January 31, 1997 Do Do Phacofragmentation System Device Premarket Notification (510(k)) Announcement by Dr Alpert at 7/26/96 August 26, 1996 Do Do Ophthalmic Panel Meeting concerning Manufacturers & Users of Lasers for Refractive Surgery [excimer] Announcement: Information for September 22, 1997 Do Do Manufacturers & Users of Lasers for Refractive Surgery [excimer] Checklist of Information Usually October 10, 1996 Do Do Submitted in an Investigational Device Exemptions (IDE) Application for Refractive Surgery Lasers [excimer] Discussion Points for Expansion of the September 5, 1997 Do Do ``Checklist of Information Usually Submitted in an Investigational Device Exemption (IDE) Application for Refractive Surgery Lasers'' Letter to Manufacturers and Users of October 10, 1996 Do Do Lasers for Refractive Surgery [excimer] Owners Certification of Lasers as PMA September 26, 1996 Do Do Approved Devices [excimer] Update on Excimer Lasers for May 20, 1996 Do Do Nearsightedness Draft Version Guidance for Clinical August 20, 1992 ODE/Division of Do Data to be Submitted for Premarket General and Approval Application for Cranial Restorative Devices Electrotherapy Stimulators (DGRD) Guidance for the Preparation of August 30, 1994 Do Do Premarket Notifications for Extended Laparoscopy Devices 510K Sterility Review Guidance July 3, 1997 Do Do Technological Reporting for Powered January 1, 1992 Do Do Muscle Stimulator 510k Submissions Draft Version Guide for Cortical August 10, 1992 Do Do Electrode 510(k) Content Electrical Muscle Stimulator (EMS) July 11, 1985 Do Do Labeling Indications, Contraindications, Warnings, etc. Galvanic Skin Response Measurement August 23, 1994 Do Do Devices--Draft Guidance for 510 (k) Content Guidance Document for the Preparation July 26, 1995 Do Do for Premarket Notification (510(k)) Applications for Therapeutic Massagers and Vibrators Guidance Document for the Preparation August 12, 1988 Do Do of IDE and PMA Applications for Bone Growth Stimulator Devices Guidance Document for the Preparation February 18, 1993 Do Do of IDE and PMA Applications for Intra- Articular Prosthetic Knee Ligament Devices Guidance Document for the Preparation July 26, 1995 Do Do of Notification (510(k)) Applications for Communication Systems (Powered and Nonpowered) and Powered Environmental Control Guidance Document for the Preparation July 26, 1995 Do Do of Notification (510(k)) Applications for Electromyograph Needle Electrodes Guidance Document for the Preparation July 26, 1995 Do Do of Notification (510(k)) Applications for Heating and Cooling Devices Guidance Document for the Preparation July 26, 1995 Do Do of Notification (510(k)) Applications for Powered Muscle Stimulators and Ultrasound Diathermy and Muscle Stimulator [[Page 9813]] Guidance Document for the Preparation July 26, 1995 Do Do of Notification (510(k)) Applications for Powered Tables and Multi-function Physical Therapy Tables Guidance Document for the Preparation July 26, 1995 Do Do of Notification (510(k)) Applications for Submerged (underwater) Exercise Equipment Guidance Document for the Preparation July 26, 1995 Do Do of Notification (510(k)) Applications of Immersion Hydrobaths Guidance Document for the Preparation July 26, 1995 Do Do of Premarket Notification (510(k)) Application for Beds Guidance Document for the Preparation July 26, 1995 Do Do of Premarket Notification [510k)] Applications for Mechanical and Powered Wheelchairs, and Motorized Three-Wheeled Vehicles Guidance for Studies for Pain Therapy May 12, 1988 Do Do Devices--Gen. Consid. in the Design of Clinical Studies for Pain- Alleviating Devices Guide for TENS 510(k) Content (Draft) August 1, 1994 Do Do Alternate Suture Labeling Resulting Do Do from the January 11, 1993 Meeting with HIMA Draft Guidance for Preparation of PMA January 18, 1995 Do Do Applications for Silicone Inflatable (Saline) Breast Prostheses Draft Guidance for Preparation of PMA May 11, 1992 Do Do Submissions of Silicone Gel-Filled Breast Prosthesis Draft Guidance for Testing of September 1, 1994 Do Do Alternative Breast Prostheses (Nonsilicone Gel-filled) Draft Guidance for the Preparation of March 31, 1995 Do Do a Premarket Notification for a Non- Interactive Wound and Burn Dressing [510(k)] Draft Guidance for the Preparation of April 1, 1995 Do Do IDE Submission for Interactive Wound and Burn Dressing Guide for 510(k) Review of Processed June 26, 1990 Do Do Human Dura Mater Letter: Core Study for Silicone Breast January 11, 1996 Do Do Implants 510(k) Information Needed for February 20, 1997 Do Do Hydroxyapatite Coated Orthopedic Implants Draft Guidance for Preparation of FDA May 11, 1992 Do Do Submissions of Silicone Gel-Filled Breast Prosthesis Calcium Phosphate (Ca-P) Coating Draft February 21, 1997 Do Do Guidance for Preparation of FDA Submissions for Orthopedic and Dental Endosseous Implants Draft Data Requirements for Ultrahigh March 28, 1995 Do Do Molecular Weight Polyethylene (Uhmupe) Used in Orthopedic Devices Draft Guidance Document for Femoral August 1, 1995 Do Do Stem Prostheses Draft Guidance Document for Testing May 1, 1995 Do Do Acetabular Cup Prostheses Draft Guidance Document for the September 5, 1996 Do Do Preparation of Premarket Notification [510(k)] Applications for Orthopedic Devices-The Basic Elements Draft Guidance for the Preparation of April 1, 1993 Do Do Premarket Notifications [510(k)]s for Cemented, Semi-Constrained Total Knee Prostheses Draft Guideline for Reviewing Spinal January 9, 1997 Do Do Fixation Device Systems Draft of Guidance Document for Testing October 25, 1995 Do Do of Orthopedic Implants with Metallic Plasma Sprayed Porous Coatings Subject to Required Post Market Surveillance Draft Outline for a Guidance Document November 1, 1993 Do Do for Testing Orthopedic Bone Cement, request for comments by December 10, 1993 Guidance Document for Testing April 20, 1996 Do Do Biodegradable Polymer Implant Devices Guidance Document for Testing Bone April 20, 1996 Do Do Anchor Devices Draft [[Page 9814]] Guidance Document for Testing Non- May 1, 1995 Do Do Articulating ``Mechanically Locked'' Modular Implant Components Guidance Document for Testing April 28, 1994 Do Do Orthopedic Implants with Modified Metallic Surfaces Apposing Bone Or Bone Cement Guidance Document For The Preparation January 10, 1995 Do Do of Premarket Notification For Ceramic Ball Hip Systems 510(k) Sterility Review Guidance July 3, 1997 Do Do Reviewers Guidance Checklist for February 21, 1997 Do Do Intramedullary Rods Reviewers Guidance Checklist for February 21, 1997 Do Do Orthopedic External Fixation Devices Draft 510(k) Guideline for General May 10, 1995 Do Do Surgical Electrosurgical Devices Draft Guidance for Arthroscopes and May 1, 1994 Do Do Accessory 510(k)s Draft Premarket Notification Review June 1, 1994 Do Do Guidance for Evoked Response Somatosensory Stimulators Draft Version 1--Biofeedback Devices-- August 1, 1994 Do Do Draft Guidance for 510(k) Content Draft Version Cranial Perforator July 13, 1994 Do Do Guidance Draft Version Neuro Endoscope Guidance July 7, 1994 Do Do Guidance on the Content and June 1, 1995 Do Do Organization of a Premarket Notification for a Medical Laser Guidelines for Reviewing Premarket Do Do Notifications that Claim Substantial Equivalence to Evoked Response Stimulators Review of ``YAG'' Lasers for Do Do Neurosurgery Draft Version--Guidance on September 12, 1994 Do Do Biocomatibility Requirements for Long Term Neurological Implants: Part 3-- Implant Model Protocol for Dermal Toxicity for Do Do Devices in Contact with Skin (Draft) Addendum to Guidance on the Content March 9, 1994 ODE/Division of Do and Format of Premarket Notification Dental Infection [510(k)] Submissions for General Control and General Purpose Disinfectants Hospital Devices (DDIGD) Guidance on Premarket Notification August 1, 1993 Do Do [510(k)] Submissions for Automated Endoscope Washers, Washer/ Disinfectors, and Disinfectors Intended for Use in Health Care Facilities Guidance on Premarket Notification August 1, 1993 Do Do [510(k)] Submissions for Surgical Gowns and Surgical Drapes Guidance on the Content and Format of December 6, 1996 Do Do Premarket Notification 510(k) Submissions for Liquid Chemical Germicides Guidance on the Content and Format of October 1, 1993 Do Do Premarket Notification [510(k)] Submissions for General Purpose Disinfectants Guidance on the Content and Format of October 1, 1993 Do Do Premarket Notification [510(k)] Submissions for Sharps Containers Draft Supplementary Guidance on the March 1, 1995 Do Do Content of Premarket Notification [510(k)] Submissions for Medical Devices with Sharps Injury Prevention Features (Anti-stick) Guidance on 510(k) Submissions for October 1, 1990 Do Do Implanted Infusion Ports Guidance on Premarket Notification March 16, 1995 Do Do [510(K)] Submissions for Short-Term and Long-Term Intravascular Catheters Guidance on the Content of Premarket March 1, 1993 Do Do Notification [510(K)] Submissions for Clinical Electronic Thermometers Guidance on the Content of Premarket March 1, 1993 Do Do Notification [510(k)] Submissions for External Infusion Pumps Guidance on the Content of Premarket April 1, 1993 Do Do Notification [510(K)] Submissions for Hypodermic Single Lumen Needles [[Page 9815]] Guidance on the Content of Premarket April 1, 1993 Do Do Notification [510(K)] Submissions for Piston Syringes 510(k) Guidance for Screw Type August 11, 1992 Do Do Endosseous Implants for Prosthetic Attachment 510(k) Information Needed for July 6, 1993 Do Do Hydroxyapatite Coated Titanium Endosseous Implants 510(k) Information Needed for August 12, 1993 Do Do Metallurgical Endosseous Implants 510(k) Information Needed for Ti- July 13, 1993 Do Do Powder Coated Titanium Endosseous Implants Draft Guidance Document for the March 3, 1997 Do Do Preparation of Premarket Notification [510(k)'S] for Dental Alloys Guidance Document for the Preparation January 23, 1995 Do Do of Premarket Notifications (510(k)'s) for Temporomandibular Joint Implants Guidance For The Arrangement and May 16, 1989 Do Do Content of a Premarket Approval (PMA) Application For An Endosseous Implant For Prosthetic Attachment Guidance for the Preparation of Do Do Premarket Notification [510(k)] for Resorbable Periodontal Barriers Information Necessary for Premarket December 9, 1996 Do Do Notification Submissions For Screw- Type Endosseous Implants Outline of Recommended Procedures for Do Do a Clinical Investigation of Endosseous Implants Under a 510(k) Outline of Recommended Procedures for Do Do Animal Laboratory Studies of Endosseous Implants Recommendations of the Dental Products Do Do Panel Subcommittee on Dental Lasers Guidance Document on Dental Handpieces July 1, 1995 Do Do Groups Capable of Testing for Latex July 28, 1997 Skin Sensitization (Addendum to #994) Draft Percutaneous Transluminal February 7, 1995 ODE/Division of Do Coronary Angioplasty Package Insert Cardiovascular, Template Respiratory and Neurological Devices (DCRND) Medical Device Labeling--Suggested April 25, 1997 Do Do Format and Content; Draft Document Guidance for Off-the-Shelf Software June 4, 1997 Do Do Use in Medical Devices; Draft Document Carotid Stent--Suggestions for Content October 26, 1996 Do Do of Submissions to the Food and Drug Administration in Support of Investigational Devices Exemption (IDE) Applications Non-Invasive Blood Pressure (NIBP) March 10, 1997 Do Do Monitor Guidance Draft Guidance for the Content of August 22, 1995 Do Do Preliminary Investigational Device Exemptions (Pre-IDE) Presentations: Teleconferences, Meetings and Written Submissions Electrocardiograph (ECG) Electrode-- February 11, 1997 Do Do Version 1.0 Electrocardiograph (ECG) Lead Switching Adapter--Version 1.0 Electrocardiograph (ECG) Surface February 11, 1997 Do Do Electrode Tester--Version 1.0 Guidance for the Preparation and December 4, 1987 Do Do Content of Applications to the Food and Drug Administration for Ventricular Assist Devices and Total Artificial Hearts (draft) Guidance for the Submission of 510(k) Do Do Premarket Notifications for Cardiovascular Intravascular Filters Preliminary Guidance for Ambulatory September 1, 1994 Do Do Electrocardiograph for Data to be Submitted to FDA in Support of Premarket Notification Applications Preliminary Guidance for Data to be December 1, 1994 Do Do Submitted in Support of Premarket Notifications for Analyzing ECGs/ Interpretive ECGs [[Page 9816]] Preliminary Guidance for Data to be April 25, 1994 Do Do Submitted to the FDA in Support of Premarket Notification Applications for External Cardioverters and Defibrillators Reviewer Checklist for Monitors: EMC, January 24, 1996 Do Do Battery and Software 510(k) Reviewer Guidelines-- Do Do Tracheostomy Tubes 868.5800 Automated Defibrillators: Operator's August 8, 1991 Do Do Shift Checklist and Manual Defibrillators: Operator's Shift Checklist Balloon Valvuloplasty Guidance For The January 1, 1989 Do Do Submission Of an IDE Application and a PMA Application Battery Guidance (Draft) (Albert July 12, 1993 Do Do Moyal) Catheter Guidance May 15, 1991 Do Do Coronary and Cerebrovascular Guidewire January 1, 1995 Do Do Guidance DCRND--Draft Guidance for Format and July 19, 1995 Do Do Content for Premarket Notification 510(k) [replaces 908] [cardiovascular, respiratory, neurological] Determining Equivalence of Intraaortic January 24, 1989 Do Do Balloon Catheters Under the 510(k) Regulations Draft 510(K) Submission Requirements January 13, 1994 Do Do for Peak Flow Meters Draft Emergency Resuscitator Guidance April 14, 1993 Do Do Draft Guidance for Implantable June 19, 1996 Do Do Cardioverter-Defibrillators Draft Guidance for the Preparation of August 1, 1993 Do Do Research and Marketing Applications for Vascular Graft Prostheses Draft Guidance for the Submission of May 1, 1995 Do Do Research and Marketing Applications for Interventional Cardiology Devices: PTCA Catheters, Atherectomy Catheters, Lasers, Intravascular Draft Guidance: Human Heart Valve June 21, 1991 Do Do Allografts Draft Premarket Notification Review June 1, 1994 Do Do Guidance for Evoked Response Somatosensory Stimulators Draft Replacement Heart Valve Guidance October 14, 1994 Do Do Draft Reviewer Guidance for July 1, 1995 Do Do Ventilators Draft Reviewer Guidance on Face Masks March 16, 1996 Do Do and Shield for CPR Draft Version--Guidance on September 12, 1994 Do Do Biocompatibility Requirements for Long Term Neurological Implants: Part 3--Implant Model Draft Version 1--Biofeedback Devices-- August 1, 1994 Do Do Draft Guidance for 510(k) Content Draft Version Cardiac Ablation March 1, 1995 Do Do Preliminary Guidance (Data to be Submitted to the FDA in Support Investigation Device Exemption Application Draft Version Cranial Perforator July 13, 1994 Do Do Guidance Draft Version Electrode Recording March 1, 1995 Do Do Catheter Preliminary Guidance (Data to be Submitted to the FDA in Support of Premarket Notifications Draft Version Guidance for Clinical August 20, 1992 Do Do Data to be Submitted for Premarket Approval Application for Cranial Electrotherapy Stimulators Draft Version Guide for Cortical August 10, 1992 Do Do Electrode 510(k) Content Draft Version Neuro Endoscope Guidance July 7, 1994 Do Do Excerpts Related to EMI from November November 1, 1993 Do Do 1993 Anesthesiology and Respiratory Devices Branch (to be used with EMI standard) Galvanic Skin Response Measurement August 23, 1994 Do Do Devices--Draft Guidance for 510(k) Content General Guidance Document: Non- September 7, 1992 Do Do Invasive Pulse Oxymeter Guidance for Oxygen Conserving Device February 1, 1989 Do Do 510(k) Review 73 BZD 868.5905 Non- continuous Ventilator Class II Guidance for Peak Flow Meters for Over- Do Do the-Counter Sale [[Page 9817]] Guidance for Safety and Effectiveness March 1, 1983 Do Do Data Required in Premarket Notification (510(k)) Applications for Blood Oxygenators Guidance for Studies for Pain Therapy May 12, 1988 Do Do Devices--General Considerations in the Design of Clinical Studies for Pain-Alleviating Devices Guidance for the Preparation of the April 1, 1990 Do Do Annual Report to the PMA Approved Heart Valve Prostheses Guide for 510(k) Review of Processed June 26, 1990 Do Do Human Dura Mater Guide for TENS 510(k) Content (Draft) August 1, 1994 Do Do Guidelines for Reviewing Premarket Do Do Notifications that Claim Substantial Equivalence to Evoked Response Stimulators Heated Humidifier Review Guidance August 30, 1991 Do Do Implantable Pacemaker Lead Testing September 1, 1989 Do Do Guidance For The Submission of a Section 510(k) Notification Implantable Pacemaker Testing Guidance January 12, 1990 Do Do Policy for Expiration Dating (DCRND October 30, 1992 Do Do RB92-G) Protocol for Dermal Toxicity Testing Do Do for Devices in Contact with Skin (Draft) Review Guidelines for Oxygen Do Do Generators and Oxygen Equipment Review of ``YAG'' Lasers for Do Do Neurosurgery Reviewer Guidance for Nebulizers, November 9, 1990 Do Do Metered Dose Inhalers, Spacers and Actuators Reviewer's Guidance for Oxygen August 30, 1991 Do Do Concentrator Draft Intravascular Brachytherapy-- May 24, 1996 Do Do Guidance for Data to be Submitted to the Food and Drug Administration in Support of Investigational Device Exemption (IDE) Applications Assessing the Safety/Effectiv. of Home- October 1, 1988 ODE/Division of Do use In Vitro Diagnostic Devices Clinical Laboratory (IVDs): Draft Points to Consider Devices (DCLD) Regarding Labeling and Premarket Submissions Review Proposal for Reagents and March 14, 1995 Do Do Analyzer Systems Data for Commercialization of Original June 10, 1996 Do Do Equipment Manufacturer, Secondary and Generic Reagents for Automated Analyzers DCLD Tier/Triage lists (include 931) May 31, 1996 Do Do Draft Criteria for Assessment of In August 31, 1995 Do Do Vitro Diagnostic Devices for Drugs of Abuse Assays Using Various Methodologies Draft Document entitled Proposed April 28, 1992 Do Do Format: Package Insert for Immunohistochemistry Products (cover memo dated 5/12/92) Draft Guidance Document for 510(k) July 29, 1992 Do Do Submission of Fecal Occult Blood Tests Draft Guidance Document for 510(k) September 30, 1991 Do Do Submission of Glycohemoglobin (Glycated or Glycosylated) Hemoglobin for IVDs Draft Guidance Document for 510(k) September 1, 1992 Do Do Submission of Immunoglobulins A,G,M,D and E Immunoglobulin System In Vitro Devices Draft Guidance for 510(k) Submission September 26, 1991 Do Do of Lymphocyte Immunophenotyping IVDs using Monoclonal Antibodies Draft Guidance For Submission of April 17, 1995 Do Do Immunohistochemistry Applications to the FDA/cover letter Draft Review Criteria for Nucleic Acid June 14, 1993 Do Do Amplification Based In Vitro Diagnostic Devices for Direct Detection of Infectious Microorganisms Draft: Premarketing Approval Review September 10, 1992 Do Do Criteria for Premarket Approval of Estrogen (ER) or Progesterone (PGR) Receptors In Vitro Diagnostic Devices Using Steroid Hormone Guidance Criteria for Cyclosporine January 24, 1992 Do Do PMAs [[Page 9818]] Labeling Requirements for Drugs of January 27, 1987 Do Do Abuse Screening Test Kits Points to Consider & Questions and October 19, 1993 Do Do Answers on Immunohistochemistry Products (cover memo dated 10/18/ 1993) Points to Consider for Cervical July 25, 1994 Do Do Cytology Devices Points to Consider for Collection of September 26, 1994 Do Do Data in Support of In-Vitro Device Submissions for 510(k) Clearance Points to Consider for Portable Blood February 20, 1996 Do Do Glucose Monitoring Devices Intended for Bedside Use in the Neonate Nursery Points to Consider for Review of February 1, 1996 Do Do Calibration and Quality Control Labeling for In Vitro Diagnostic Devices/Cover Letter dated 3/14/1996 Review Criteria for In Vitro February 1, 1994 Do Do Diagnostic Devices for the Assessment of Thyroid Autoantibodies using Indirect Immunofluorescence Assay (IFA), Indirect Review Criteria for Assessment of July 15, 1994 Do Do Alpha-Fetoprotein (AFP) in vitro Diagnostic Devices for Fetal Open Neural Tube Defects Using Immunological Test Methodologies Review Criteria for Assessment of May 31, 1991 Do Do Antimicrobial Susceptibility Devices Review Criteria for Assessment of July 15, 1991 Do Do Cytogenetic Analysis Using Automated and Semi-Automated Chromosome Analyzers Review Criteria for Assessment of September 27, 1995 Do Do Human Chorionic Gonadotropin (hCG) In Vitro Diagnostic Devices (IVDs) Review Criteria for Assessment of In January 1, 1992 Do Do Vitro Diagnostic Devices for Direct Detection of Chlamydiae in Clinical Specimens Review Criteria for Assessment of In July 6, 1993 Do Do Vitro Diagnostic Devices for Direct Detection of Mycobacterium Spp. [Tuberculosis (TB)] Review Criteria for Assessment of September 17, 1992 Do Do Laboratory Tests for the Detection of Antibodies to Helicobacter pylori Review Criteria for Assessment of February 14, 1996 Do Do Portable Blood Glucose In Vitro Diagnostic Devices Using Glucose Oxidase, Dehydrogenase, or Hexokinase Methodology Review Criteria for Blood Culture August 12, 1991 Do Do Systems Review Criteria for Devices Assisting May 31, 1990 Do Do in the Diagnosis of C. Difficile Associated Diseases Review Criteria for Devices Intended December 30, 1991 Do Do for the Detection of Hepatitis B ``e'' Antigen and Antibody to HBe Review Criteria for In Vitro August 1, 1992 Do Do Diagnostic Devices for Detection of IGM Antibodies to Viral Agents Review Criteria for In Vitro February 15, 1996 Do Do Diagnostic Devices that Utilize Cytogenetic In Situ Hybridization Technology for the Detection of Human Genetic Mutations (Germ Line and Review Criteria For Premarket Approval May 15, 1992 Do Do of In Vitro Diagnostic Devices for Detection of Antibodies to Parvovirus B19 Review Criteria for the Assessment of March 2, 1993 Do Do Allergen-Specific Immunoglobulin E (IGE) In-Vitro Diagnostic Devices Using Immunological Test Methodologies Review Criteria for the Assessment of September 1, 1992 Do Do Anti-nuclear Antibodies (ANA) In- Vitro Diagnostic Devices Using Indirect Immunofluorescence Assay (IFA), Guidance Document for the Submission September 19, 1996 Do Do of Tumor Associated Antigen Premarket Notification [510(k)] to FDA [[Page 9819]] Review Criteria for Assessment of February 21, 1997 Do Do Rheumatoid Factor (RF) In Vitro Diagnostic Devices Using Engzyme- Linked Immunoassay (EIA), Enzyme Linked Immunosorbent Assay (ELISA), Particle Guidance for 510(k)s on Cholesterol July 14, 1995 Do Do Tests for Clinical Laboratory, Physicians' Office Laboratory, and Home Use Clinical Utility and Premarket May 3, 1991 ODE Do Approval #P91-1 (blue book memo) Criteria for Panel Review of PMA January 30, 1986 Do Do Supplements #P86-3 (blue book memo) Panel Report and Recommendations on April 18, 1986 Do Do PMA Approvals #P86-5 (blue book memo) Panel Review of ``Me-Too'' Devices July 1, 1986 Do Do #P86-6 (blue book memo) Panel Review of Premarket Approval May 3, 1991 Do Do Applications #P91-2 (blue book memo) PMA Compliance Program #P91-3 (blue May 3, 1991 Do Do book memo) PMA Filing Decisions #P90-2 (blue book May 18, 1990 Do Do memo) PMA Refuse to File Procedures #P94-1 May 20, 1994 Do Do (blue book memo) PMA Supplements: ODEs letter to April 24, 1990 Do Do manufacturers; identifies situations which may require the submission of a PMA supplement (When PMA Supplements are Required) #P90-1 (blue book memo) PMAs--Early Review and Preparation of January 27, 1986 Do Do Summaries of Safety and Effectiveness #P86-1 (blue book memo) Premarket Approval Application (PMA) July 8, 1994 Do Do Closure #P94-1 (blue book memo) Review and Approval of PMAs of October 22, 1990 Do Do Licensees #P86-4 (blue book memo) Review of Final Draft Medical Device August 29, 1991 Do Do Labeling #P91-4 (blue book memo) Assignment of Review Documents #I90-2 August 24, 1990 Do Do (blue book memo) Document Review Processing #I91-1 February 12, 1992 Do Do (blue book memo) Integrity of Data and Information May 29, 1991 Do Do Submitted to ODE #I91-2 (blue book memo) Meetings with the Regulated Industry November 20, 1989 Do Do #I89-3 (blue book memo) Nondisclosure of Financially Sensitive March 5, 1992 Do Do Information #I92-1 (blue book memo) Policy Development and Review February 15, 1990 Do Do Procedures #I90-1 (blue book memo) Telephone Communications Between ODE January 29, 1993 Do Do Staff and Manufacturers #I93-1 (blue book memo) Delegation of IDE Actions #D88-1 (blue April 26, 1988 Do Do book memo) Goals and Initiatives for the IDE July 12, 1995 Do Do Program #D95-1 (blue book memo) IDE Refuse to Accept Procedures #D94-1 May 20, 1994 Do Do (blue book memo) Implementation of the FDA/HCFA September 15, 1995 Do Do Interagency Agreement Regarding Reimbursement Categorization of Investigational Devices, Att. A Interagency Agreement, Att. B Criteria Overdue IDE Annual Progress Report July 23, 1993 Do Do Procedures #D93-1 (blue book memo) Review of IDEs for Feasibility Studies May 17, 1989 Do Do #D89-1 (blue book memo) Consolidated Review of Submissions for October 19, 1990 Do Do Diagnostic Ultrasound Equipment, Accessories and Related Measurement Devices #G90-2 (blue book memo) Consolidated Review of Submissions for October 19, 1990 Do Do Lasers and Accessories #G90-1 (blue book memo) Device Labeling Guidance #G91-1 (blue March 8, 1991 Do Do book memo) [[Page 9820]] Documentation and Resolution of December 23, 1993 Do Do Differences of Opinion on Product Evaluations #G93-1 (blue book memo) ODE Regulatory Information for the May 15, 1987 Do Do Office of Compliance - Information Sharing Procedures #G87-2 (blue book memo) PMA/510(k) Expedited Review #G94-2 May 20, 1994 Do Do (blue book memo) PMA/510(k) Triage Review Procedures May 20, 1994 Do Do #G94-1 (blue book memo) Review of Laser Submissions #G88-1 April 15, 1988 Do Do (blue book memo) Toxicology Risk Assessment Committee August 9, 1989 Do Do #G89-1 (blue book memo) Use of International Standard ISO- May 1, 1995 Do Do 10993, ``Biological Evaluation of Medical Devices Part 1: Evaluation and Testing'' (Replaces #G87-1 #8294) (blue book memo) 510(k) Additional Information July 23, 1993 Do Do Procedures #K93-1 (blue book memo) 510(k) Refuse to Accept Procedures May 20, 1994 Do Do #K94-1 (blue book memo) 510(k) Sign-Off Procedures #K94-2 June 3, 1994 Do Do (blue book memo) 510(k) Sterility Review Guidance - and February 12, 1990 Do Do Revision of 11/18/1994 #K90-1 (blue book memo) Cover Letter: 510(k) Requirements November 21, 1995 Do Do During Firm-Initiated Recalls; Attachment A: Guidance on Recall and Premarket Notification Review Procedures During Firm-Initiated Recalls of Legally Marketed Drugs (blue book #K95-1) Guidance on the Center for Devices and June 30, 1986 Do Do Radiological Health's Premarket Notification Review Program #K86-3 (blue book memo) Premarket Notification - Consistency February 28, 1989 Do Do of Reviews #K89-1 (blue book memo) Review of 510(k)s for Computer August 29, 1991 Do Do Controlled Medical Devices #K91-1 (blue book memo) Continued Access to Investigational July 15, 1996 Do Do Devices During PMA Preparation and Review (blue book memo) Use of IEC 60601 Standards Medical October 10, 1997 Do Do Electrical Equipment; Draft Document [blue book memo #G97-X] (blue book memo #K97-1) Deciding When January 10, 1997 Do Do to Submit a 510(k) for a Change to an Existing Device [see CDRH F-O-D #935] Memorandum of Understanding Regarding August 9, 1996 Do Do Patient Labeling Review (blue book memo #G96-3)) #D95-2, Attachment A (Interagency September 15, 1995 Do Do Agreement between FDA & HCFA) #D95-2, Attachment B (Criteria for September 15, 1995 Do Do Categorization of Investigational Devices (HCFA) 510(k) Quality Review Program (blue March 29, 1996 Do Do book memo) Distribution and Public Availability October 10, 1997 Do Do of PMA Summary of Safety and Effectiveness Data Packages Document Review by the Office of the June 6, 1996 Do Do Chief Counsel (blue book memo G96-1)) Draft Guidance for Testing MR May 22, 1996 Do Do Interaction with Aneurysm Clips HCFA Reimbursement Categorization September 15, 1995 Do Do Determinations for FDA-approved IDEs ODE Executive Secretary Guidance August 7, 1987 Do Do Manual Tripartie Biocompatibility Guidance April 24, 1984 Do Do Guidance for Submitting Do Do Reclassification Petition Product Development Protocol October 1, 1997 Do Do Exemption from Reporting and Record September 16, 1981 Do Do keeping Requirements for Certain Sunlamp Product Manufacturers [[Page 9821]] Reporting of New Model Numbers to June 14, 1983 Do Do Existing Model Families ---------------------------------------------------------------------------------------------------------------- IV. Guidance Documents Issued by the Center for Drug Evaluation and Research (CDER) ---------------------------------------------------------------------------------------------------------------- How to Obtain a Hard Copy of Grouped by Intended the Document (Name and Name of Document Date of Issuance User or Regulatory Address, Phone, FAX, E-mail, Activity or Internet) ---------------------------------------------------------------------------------------------------------------- Consumer-Directed Broadcast August 12, 1997 Advertising (Draft) Office of Training and Advertisements Communications, Drug Information Branch, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-4573 or Internet at http:// www.fda.gov/cder/guidance/ index.htm Promoting Med Products (Multicenter) January 5, 1998 Do Do Aerosol Steroid Product Safety January 12, 1998 Do Do Information in Prescript. Drug Advertising and Promotional Labeling DDMAC 2 Dissemination of Reprints of Certain October 8, 1996 Advertising Do Published, Original Data Funded Dissemination of Reference October 8, 1996 Do Do Texts Antifungal (topical) February 24, 1990 Biopharmaceutic Drug Information Branch (Draft) Antifungal (vaginal) February 24, 1990 Do Do Food-Effect Bioavailability and December 30, 1997 Do Do Bioequivalence In Vivo Bioequivalence Studies Based December 30, 1997 Do Do on Population and Individual Bioequivalence Approaches Pharmacokinetics and Pharmacodynamics June 16, 1997 Do Drug Information Branch or in Patients with Impaired Renal Internet at http:// Function: Study Design, Data www.fda.gov/cder/guidance/ Analysis, and Impact on Dosing and index.htm Labeling Population Pharmacokinetics September 18, 1997 Do Do Waiver Policy March 29, 1993 Do Drug Information Branch Acetohexamide (tablets) In Vivo August 1, 1988 Biopharmaceutic Do Bioequivalence and In Vitro Dissolution Testing Albuterol Inhalation Aerosols (Metered January 27, 1994 Do Do Dose Inhalers) In Vivo Bioequivalence and In Vitro Dissolution Testing Albuterol Sulfate (tablets) In Vivo May 29, 1987 Do Do Bioequivalence and In Vitro Dissolution Testing Allopurinol (tablets) In Vivo July 15, 1985 Do Do Bioequivalence and In Vitro Dissolution Testing Alprazolam Tablets In Vivo November 27, 1992 Do Do Bioequivalence and In Vitro Dissolution Testing Amiloride Hydrochloride (tablets) In March 29, 1985 Do Do Vivo Bioequivalence and In Vitro Dissolution Testing Aminophylline (suppositories) In Vivo July 5, 1983 Do Do Bioequivalence and In Vitro Dissolution Testing Amitriptyline Hydrochloride (tablets) July 5, 1983 Do Do In Vivo Bioequivalence and In Vitro Dissolution Testing Amoxapine (tablets) In Vivo August 5, 1988 Do Do Bioequivalence and In Vitro Dissolution Testing Amoxicillin (capsules, tablets and June 10, 1988 Do Do suspension) In Vivo Bioequivalence and In Vitro Dissolution Testing Approaches to Statistical Data November 1, 1985 Do Do Analysis of Bioavailability/ Bioequivalence Studies Atenolol (tablets) In Vivo October 6, 1988 Do Drug Information Branch or Bioequivalence and In Vitro Internet at http:// Dissolution Testing www.fda.gov/cder/guidance/ index.htm Baclofen (tablets) In Vivo May 5, 1986 Do Drug Information Branch Bioequivalence and In Vitro Dissolution Testing Bioavailability Policies and Do Do Guidelines [[Page 9822]] Bumetanide Tablets In Vivo April 23, 1993 Do Drug Information Branch or Bioequivalence and In Vitro Interent at http:// Dissolution Testing www.fda.gov/cder/guidance/ index.htm Buspirone Hydrochloride Tablets In August 13, 1993 Do Do Vivo Bioequivalence and In Vitro Dissolution Testing Captopril Tablets In Vivo May 13, 1993 Do Do Bioequivalence and In Vitro Dissolution Testing Carbamazepine (tablets) In Vivo January 20, 1988 Do Drug Information Branch Bioequivalence and In Vitro Dissolution Testing Carbidopa and Levodopa Tablets In Vivo June 19, 1992 Do Drug Information Branch or Bioequivalence and In Vitro Internet at http:// Dissolution Testing www.fda.gov/cder/guidance/ index.htm Cefaclor Capsules and Suspension In April 23, 1993 Do Do Vivo Bioequivalence and In Vitro Dissolution Testing Cefadroxil (capsules, tablets and October 7, 1986 Do Drug Information Branch suspension) In Vivo Bioequivalence and In Vitro Dissolution Testing Cephalexin (tablets and capsules) In March 19, 1987 Do Do Vivo Bioequivalence and In Vitro Dissolution Testing Cephradine (Capsule and Suspension) September 10, 1986 Do Do Chlordiazepoxide (Tablets) July 5, 1983 Do Do Chlordiazepoxide Hydrochloride July 5, 1983 Do Do (Capsules) Chlorpropamide (Tablets) July 5, 1983 Do Do Chlorthalidone (Tablets) July 5, 1983 Do Do Cholestyramine Powder In Vitro July 15, 1993 Do Drug Information Branch or Bioequivalence Internet at http:// www.fda.gov/cder/guidance/ index.htm Cimetidine Tablets In Vivo June 12, 1992 Do Do Bioequivalence and In Vitro Dissolution Testing Clindamycin Hydrochloride (capsules) May 31, 1988 Do Drug Information Branch In Vivo Bioequivalence and In Vitro Dissolution Testing Clofibrate (Capsules) April 7, 1986 Do Do Clonidine Hydrochloride (Tablets) December 5, 1984 Do Do Clorazepate Dipotassium (Capsules and February 17, 1987 Do Do Tablets) Clozapine (Tablets) In Vivo November 15, 1996 Do Drug Information Branch or Bioequivalence and In Vitro Internet at http:// Dissolution Testing www.fda.gov/cder/guidance/ index.htm Controlled Release Dosage Forms: September 10, 1985 Do Drug Information Branch Issues and Controversies (Conference Report) Corticosteroids, Dermatologic June 2, 1995 Do Do (topical) In Vivo Cyclobenzaprine Hydrochloride January 25, 1988 Do Do (tablets) In Vivo Bioequivalence and In Vitro Dissolution Testing Desipramine Hydrochloride (Tablets) September 22, 1987 Do Do Diazepam (Tablets) July 8, 1985 Do Do Diclofenac Sodium (tablets) In Vivo October 6, 1994 Do Do Bioequivalence and In Vitro Dissolution Testing Dicyclomine Hydrochloride (Tablets and August 1, 1984 Do Do Capsules) Diflunisal Tablets In Vivo May 16, 1992 Do Drug Information Branch or Bioequivalence and In Vitro Internet at http:// Dissolution Testing www.fda.gov/cder/guidance/ index.htm Diltiazem Hydrochloride Tablets In May 16, 1992 Do Do Vivo Bioequivalence and In Vitro Dissolution Testing Dipyridamole (Tablets) September 25, 1987 Do Drug Information Branch Disopyramide Phosphate (Capsules) July 9, 1985 Do Do Dissolution Testing (General) April 1, 1978 Do Do Dissolution Testing of Immediate August 25, 1997 Do Drug Information Branch or Release Solid Oral Dosage Forms Internet at http:// www.fda.gov/cder/guidance/ index.htm Division Guidelines for the Evaluation April 18, 1984 Do Drug Information Branch of Controlled Release Drug Products Doxepin Hydrochloride (Capsules) October 9, 1986 Do Do Doxycycline Hyclate (Capsules and April 11, 1988 Do Do Tablets) Erythromycin Capsules (Enteric Coated September 21, 1988 Do Do Pellets) Estropipate Tablets In Vivo August 26, 1992 Do Drug Information Branch or Bioequivalence and In Vitro Internet at http:// Dissolution Testing www.fda.gov/cder/guidance/ index.htm Extended Release Oral Dosage Forms: September 26, 1997 Do Do Development, Evaluation, and Application of In Vitro/In Vivo Correlations (BP2) [[Page 9823]] Fenoprofen (capsules and tablets) In February 3, 1988 Do Drug Information Branch Vivo Bioequivalence and In Vitro Dissolution Testing Flurazepam Hydrochloride (capsules) In October 15, 1985 Do Do Vivo Bioequivalence and In Vitro Dissolution Testing Flurbiprofen (tablets) In Vivo June 8, 1995 Do Do Bioequivalence and In Vitro Dissolution Testing Format and Content of the Human February 1, 1987 Do Do Pharmacokinetics and Bioavailability Section of an Application*\1\ Gemfibrozil Capsules or Tablets In June 15, 1992 Do Drug Information Branch or Vivo Bioequivalence and In Vitro Internet at http:// Dissolution Testing www.fda.gov/cder/guidance/ index.htm Glipizide (Tablets) In Vivo April 23, 1993 Do Do Bioequivalence and In Vitro Dissolution Testing Glyburide Tablets In Vivo April 23, 1993 Do Do Bioequivalence and In Vitro Dissolution Testing Guanabenz Acetate Tablets In Vivo April 23, 1993 Do Do Bioequivalence and In Vitro Dissolution Testing Haloperidol (tablets) In Vivo April 30, 1987 Do Drug Information Branch Bioequivalence and In Vitro Dissolution Testing Hydrochlorothiazide (tablets) In Vivo September 28, 1987 Do Do Bioequivalence and In Vitro Dissolution Testing Hydroxychloroquine Sulfate (tablets) December 28, 1995 Do Do In Vivo Bioequivalence and In Vitro Dissolution Testing Hydroxyzine Hydrochloride (tablets) March 4, 1986 Do Do (dissolution only) Hydroxyzine Pamoate (capsules) In Vivo September 28, 1987 Do Do Bioequivalence and In Vitro Dissolution Testing Indapamide (tablets) In Vivo April 23, 1993 Do Do Bioequivalence and In Vitro Dissolution Testing Indomethacin (capsules) In Vivo January 27, 1988 Do Do Bioequivalence and In Vitro Dissolution Testing Isopropamide Iodide (tablets) In Vivo May 12, 1982 Do Do Bioequivalence and In Vitro Dissolution Testing Isosorbide Dinitrate (chewable September 22, 1987 Do Do tablets, oral tablets, and sublingual tablets) In Vivo Bioequivalence and In Vitro Dissolution Testing Isosorbide Dinitrate Controlled November 6, 1985 Do Do Release Products Ketoprofen (capsules) In Vivo April 23, 1993 Do Do Bioequivalence and In Vitro Dissolution Testing Leucovorin Calcium (tablets) In Vivo August 4, 1988 Do Do Bioequivalence and In Vitro Dissolution Testing Lorazepam (tablets) In Vivo September 16, 1987 Do Do Bioequivalence and In Vitro Dissolution Testing Loxapine Succinate (capsules) In Vivo September 10, 1987 Do Do Bioequivalence and In Vitro Dissolution Testing Maprotiline Hydrochloride (tablets) In August 27, 1987 Do Do Vivo Bioequivalence and In Vitro Dissolution Testing Meclofenamate Sodium (capsules) In November 12, 1986 Do Do Vivo Bioequivalence and In Vitro Dissolution Testing Medroxyprogesterone Acetate (tablets) September 17, 1987 Do Do In Vivo Bioequivalence and In Vitro Dissolution Testing Megestrol Acetate (tablets) In Vivo August 17, 1987 Do Do Bioequivalence and In Vitro Dissolution Testing Metaproterenol Sulfate (tablets) In March 18, 1988 Do Do Vivo Bioequivalence and In Vitro Dissolution Testing Metaproterenol Sulfate and Albuterol June 27, 1989 Do Do Metered Dose Inhalers In Vitro Metaproterenol Sulfate and Albuterol June 27, 1989 Do Do Metered Dose Inhalers In Vitro Methylprednisolone (tablets) In Vivo June 12, 1986 Do Do Bioequivalence and In Vitro Dissolution Testing Metoclopramide Hydrochloride (tablets) December 27, 1984 Do Do In Vivo Bioequivalence and In Vitro Dissolution Testing Metoprolol Tartrate (tablets) In Vivo June 12, 1992 Do Do Bioequivalence and In Vitro Dissolution Testing Minoxidil (Tablets) June 12, 1986 Do Do Nadolol (tablets) In Vivo May 16, 1992 Do Do Bioequivalence and In Vitro Dissolution Testing Nafcillin Sodium (Capsules and September 10, 1987 Do Do Tablets) Nalidixic Acid (Tablets) August 19, 1997 Do Do [[Page 9824]] Naproxen (tablets) In Vivo June 8, 1995 Do Do Bioequivalence and In Vitro Dissolution Testing Nitrofurantion Macrocrystalline January 10, 1986 Do Do (capsules) In Vivo Bioequivalence and In Vitro Dissolution Testing Nitroglycerin (Ointment) December 17, 1986 Do Do Norethindrone and Ethinyl Estradiol March 18, 1988 Do Do (tablets) In Vivo Bioequivalence and In Vitro Dissolution Testing Norethindrone and Mestranol (tablets) May 13, 1988 Do Do In Vivo Bioequivalence and In Vitro Dissolution Testing Nortriptyline Hydrochloride (capsules) June 12, 1992 Do Do In Vivo Bioequivalence and In Vitro Dissolution Testing Oral Extended (controlled) Release In September 9, 1993 Do Drug Information Branch or Vivo Bioequivalence and In Vitro Internet at http:// Dissolution Testing www.fda.gov/cder/guidance/ index.htm Orphenadrine Citrate (tablets) In Vivo July 22, 1983 Do Drug Information Branch Bioequivalence and In Vitro Dissolution Testing Pentoxifylline (extended-release December 22, 1995 Do Do tablets) In Vivo Bioequivalence and In Vitro Dissolution Testing Perphenazine (tablets) In Vivo August 27, 1987 Do Do Bioequivalence and In Vitro Dissolution Testing Perphenazine/Amitriptyline (tablets) August 27, 1987 Do Do In Vivo Bioequivalence and In Vitro Dissolution Testing Pharmacokinetic Considerations in Drug N/A Do Do Studies Phenylbutazone Oxyphenbutazone September 28, 1987 Do Do (capsules and tablets) In Vivo Bioequivalence and In Vitro Dissolution Testing Phenytoin/Phenytion Sodium (capsules, March 4, 1994 Do Do tablets, suspension) In Vivo Bioequivalence and In Vitro Dissolution Testing Pindolol (tablets) In Vivo April 23, 1993 Do Do Bioequivalence and In Vitro Dissolution Testing Piroxicam (capsules) In Vivo June 15, 1992 Do Do Bioequivalence and In Vitro Dissolution Testing Potassium Chloride (slow-release May 15, 1987 Do Do tablets and capsules) In Vivo Bioequivalence and In Vitro Dissolution Testing Prazepam (capsules and tablets) In July 26, 1988 Do Do Vivo Bioequivalence and In Vitro Dissolution Testing Prednisone (tablets) (dissolution July 10, 1985 Do Do only) Probenecid (Tablets) July 26, 1983 Do Do Procainamide Hydrochloride September 28, 1987 Do Do Propoxyphene Napsylate with March 26, 1980 Do Do Acetaminphen (Tablets) Propranolol Hydrochloride (tablets) In August 1, 1984 Do Do Vivo Bioequivalence and In Vitro Dissolution Testing Propylthiouracil (tablets) In Vivo August 13, 1986 Do Do Bioequivalence and In Vitro Dissolution Testing Quinidine Gluconate (tablets, September 22, 1987 Do Do controlled release) In Vivo Bioequivalence and In Vitro Dissolution Testing Ranitidine Hydrochloride (tablets) In April 23, 1993 Do Do Vivo Bioequivalence and In Vitro Dissolution Testing Rifampin (capsules) In Vivo September 8, 1988 Do Do Bioequivalence and In Vitro Dissolution Testing Ritodrine Hydrochloride (tablets) In August 27, 1987 Do Do Vivo Bioequivalence and In Vitro Dissolution Testing Selegiline Hydrochloride (tablets) In December 22, 1995 Do Do Vivo Bioequivalence and In Vitro Dissolution Testing Silver Sulfadiazine (cream) May 7, 1987 Do Do Spironolactone (Tablets) January 1, 1986 Do Do Statistical Procedure for July 1, 1992 Do Do Bioequivalence Studies Using a Standard Two-Treatment Crossover Design Submission of Data for Bioequivalence N/A Do Do Studies in Computer Format Sulfasalazine (tablets) In Vivo October 8, 1987 Do Do Bioequivalence and In Vitro Dissolution Testing Sulfinpyrazone (Capsules and Tablets) September 25, 1987 Do Do Sulfones (tablets) In Vivo November 7, 1986 Do Do Bioequivalence and In Vitro Dissolution Testing [[Page 9825]] Sulindac (tablets) In Vivo July 18, 1988 Do Do Bioequivalence and In Vitro Dissolution Testing Temazepam (Capsules) August 8, 1985 Do Do Theophylline (conventional dosage September 1, 1984 Do Do form) In Vivo Bioequivalence and In Vitro Dissolution Testing Timolol Maleate (tablets) In Vivo August 9, 1988 Do Do Bioequivalence and In Vitro Dissolution Testing Tolazamide (tablets) In Vivo May 30, 1986 Do Do Bioequivalence and In Vitro Dissolution Testing Tolbutamide (tablets) In Vivo December 1, 1983 Do Do Bioequivalence and In Vitro Dissolution Testing Tolmetin Sodium (tablets and capsules) October 6, 1994 Do Do In Vivo Bioequivalence and In Vitro Dissolution Testing Trazodone Hydrochloride (tablets) In April 30, 1988 Do Do Vivo Bioequivalence and In Vitro Dissolution Testing Triazolam (tablets) In Vivo December 24, 1992 Do Do Bioequivalence and In Vitro Dissolution Testing Trimipramine Maleate (capsules) In August 18, 1987 Do Do Vivo Bioequivalence and In Vitro Dissolution Testing Verapamil Hydrochloride (tablets) In July 18, 1985 Do Do Vivo Bioequivalence and In Vitro Dissolution Testing Submission of Documentation in Drug July 15, 1997 Chemistry (Draft) Drug Information Branch or Applications for Container Closure Internet at http:// Systems Used for the Packaging of www.fda.gov/cder/guidance/ Human Drugs and Biologics index.htm Submitting Supporting Chemistry November 1, 1991 Do Drug Information Branch Documentation in Radiopharmaceutical Drug Applications* Tracking of NDA and ANDA N/A Do Do Reformulations for Solid, Oral, Immediate Release Drug Products (Docket No. 89N-0066) Drug Master Files September 1, 1989 Chemistry Drug Information Branch or Internet at http:// www.fda.gov/cder/guidance/ index.htm FDA's Policy Statement for the May 1, 1992 Do Do Development of New Stereoisomeric Drugs Format and Content for the CMC Section September 1, 1994 Do Do of an Annual Report (CMC 1) Format and Content of the Chemistry, February 1, 1987 Do Drug Information Branch Manufacturing and Controls Section of an Application* Format and Content of the Microbiology February 1, 1987 Do Do Section of an Application* (Docket No. 85D-0245) Reviewer Guidance: Validation of November 1, 1994 Do Drug Information Branch or Chromatographic Methods (CMC 3) Internet at http:// www.fda.gov/cder/guidance/ index.htm Submission of an Environmental November 13, 1995 Do Drug Information Branch or Assessment in Human Drug Applications Internet at http:// and Supplements (CMC 6) www.fda.gov/cder/guidance/ index.htm Submission of Chemistry, Manufacturing November 1, 1994 Do Drug Information Branch or and Controls Information for Internet at http:// Synthetic Peptide Substances (CMC 4) www.fda.gov/cder/guidance/ index.htm Submission of Documentation for November 1, 1994 Do Drug Information Branch or Sterilization Process Validation Internet at http:// Applications for Human and Veterinary www.fda.gov/cder/guidance/ Drug Products (CMC 2) index.htm Submitting Documentation for Packaging February 1, 1987 Do Do for Human Drugs and Biologics* Submitting Documentation for the February 1, 1987 Do Drug Information Branch Manufacturing of and Controls for Drug Products* Submitting Documentation for the February 1, 1987 Do Do Stability of Human Drugs and Biologics* Submitting Samples and Analytical Data February 1, 1987 Do Drug Information Branch or for Methods Validation* Internet at http:// www.fda.gov/cder/guidance/ index.htm Submitting Supporting Documentation in February 1, 1987 Do Do Drug Applications for the Manufacture of Drug Substances* SUPAC IR-Immediate-Release Solid Oral November 30, 1995 Do Drug Information Branch or or Dosage Forms: Scale-Up and Post- Internet at http:// Approval Changes: Chemistry, www.fda.gov/cder/guidance/ Manufacturing and Controls, In Vitro index.htm Dissolution Testing, and In Vivo Bioequivalence Documentation (CMC 5) [[Page 9826]] SUPAC-IR: Immediate Release Solid Oral October 21, 1997 Do Drug Information Branch or Dosage Forms; Manufacturing Equipment Internet at http:// Addendum (CMC 9) www.fda.gov/cder/guidance/ index.htm SUPAC-IR Questions and Answers February 18, 1997 Do Do SUPAC-MR: Modified Release Solid Oral October 6, 1997 Do Drug Information Branch or Dosage Forms: Scale-Up and Internet at http:// Postapproval Changes: Chemistry, www.fda.gov/cder/guidance/ Manufacturing, and Controls, In Vitro index.htm Dissolution Testing, and In Vivo Bioequivalence Documentation (CMC 8) SUPAC-SS--Nonsterile Semisolid Dosage June 13, 1997 Do Drug Information Branch or Forms; Scale-Up and Postapproval Internet at http:// Changes: Chemistry, Manufacturing, www.fda.gov/cder/guidance/ and Controls; In Vitro Release index.htm Testing and In Vivo Bioequivalence Documentation (CMC 7) Abuse Liability Assessment July 1, 1990 Clinical (Draft) Drug Information Branch Clinical Development Programs for January 10, 1997 Do Drug Information Branch or Drugs, Devices, and Biological Internet at http:// Products for the Treatment of www.fda.gov/cder/guidance/ Rheumatoid Arthritis (RA) index.htm Clinical Evaluation of Agents Used in April 1, 1994 Do Drug Information Branch the Prevention or Treatment of Postmenopausal Osteoporosis Clinical Evaluation of Anti-Anginal January 1, 1989 Do Do Drugs Clinical Evaluation of Anti-Arrhythmic July 1, 1985 Do Do Drugs Clinical Evaluation of May 1, 1988 Do Do Antihypertensive Drugs Clinical Evaluation of Drugs for the December 1, 1987 Do Do Treatment of Congestive Heart Failure Clinical Evaluation of Drugs for the N/A Do Do Treatment of Peripheral Vascular Disease Clinical Evaluation of Drugs for N/A Do Do Ulcerative Colitis (3rd draft) Clinical Evaluation of Motility- N/A Do Do Modifying Drugs Clinical Evaluation of Weight-Control July 12, 1995 Do Do Drugs Conducting a Clinical Safety Review of November 22, 1996 Do Do a New Product Application and Preparing a Report on the Review (96N- 0443) Development and Evaluation of Drugs February 12, 1992 Do Do for the Treatment of Psychoactive Substance Use Disorders Evaluating Clinical Studies of February 18, 1997 Do Drug Information Branch or Antimicrobials in the Division of Internet at http:// Anti-Infective Drug Products www.fda.gov/cder/guidance/ index.htm FDA Approval of New Cancer Treatment March 13, 1997 Do Do Uses for Marketed Drug and Biological Products Points to Consider for System N/A Do Drug Information Branch Inflammatory Response Syndrome (SIRS) 1st Draft Points to Consider in the Preparation September 1, 1991 Do Do of IND Applications for New Drugs Intended for the Treatment of HIV- Infected Individuals Providing Clinical Evidence of March 13, 1997 Do Drug Information Branch or Effectiveness for Human Drug and Internet at http:// Biological Products www.fda.gov/cder/guidance/ index.htm Clinical Evaluation of Analgesic Drugs December 1, 1992 Clinical Drug Information Branch (FDA 93-3093) Clinical Evaluation of Antacid Drugs April 1, 1978 Do Drug Information Branch (FDA 78-3065) Clinical Evaluation of Anti-Infective November 1, 1992 Do Drug Information Branch Drugs (Systemic) (FDA 77-3046) Clinical Evaluation of Anti- May 26, 1993 Do Drug Information Branch Inflammatory and Antirheumatic Drugs (adults and children) Clinical Evaluation of Antianxiety N/A Do Drug Information Branch Drugs (FDA 77-3043) Clinical Evaluation of Antidepressant September 1, 1977 Do Drug Information Branch Drugs (FDA 77-3042) Clinical Evaluation of Antidiarrheal September 1, 1977 Do Drug Information Branch Drugs (FDA 78-3049) Clinical Evaluation of Antiepileptic January 1, 1981 Do Drug Information Branch Drugs (adults and children) (FDA 81- 3110) Clinical Evaluation of Bronchodilator N/A Do Drug Information Branch Drugs (FDA 79-3073) Clinical Evaluation of Combination March 20, 1995 Do Drug Information Branch Estrogen/Progestin-Containing Drug Products Used for Hormone Replacement Therapy of Postmenopausal Women [[Page 9827]] Clinical Evaluation of Drugs to November 1, 1978 Do Drug Information Branch Prevent, Control and/or Treat Periodontal Disease (FDA 79-3074) Clinical Evaluation of Gastric September 1, 1977 Do Drug Information Branch Secretory Depressant (GSD) Drugs (FDA 78-3050) Clinical Evaluation of General May 1, 1982 Do Drug Information Branch Anesthetics (FDA 78-3052) Clinical Evaluation of Hypnotic Drugs September 1, 1977 Do Drug Information Branch (FDA 78-3051) Clinical Evaluation of Laxative Drugs April 1, 1978 Do Drug Information Branch (FDA 78-3067) Clinical Evaluation of Lipid-Altering N/A Do Drug Information Branch Agents in Adults and Children (FDA 80- 3103) Clinical Evaluation of Local May 1, 1982 Do Drug Information Branch Anesthetics (FDA 82-3053) Clinical Evaluation of Psychoactive July 1, 1979 Do Drug Information Branch Drugs in Infants and Children (FDA 79- 3055) Clinical Evaluation of October 1, 1981 Do Drug Information Branch Radiopharmaceutical Drugs (FDA 81- 3120) Content and Format for Pediatric Use May 24, 1996 Do Drug Information Branch or Supplements (CLIN 1) Internet at http:// www.fda.gov/cder/guidance/ index.htm Content and Format of Investigational November 20, 1995 Do Drug Information Branch or New Drug Applications (INDs) for Internet at http:// Phase 1 Studies of Drugs, Including www.fda.gov/cder/guidance/ Well-Characterized, Therapeutic, index.htm Biotechnology-Derived Products (CLIN 2) Development of Vaginal Contraceptive April 19, 1995 Do Drug Information Branch Drugs (NDA) (95D-0004) Drug Metabolism/Drug Interaction April 7, 1997 Do Drug Information Branch or Studies in the Drug Development Internet at http:// Process: Studies In Vitro (CLIN 3) www.fda.gov/cder/guidance/ index.htm FDA Requirements for Approval of Drugs January 29, 1991 Do Drug Information Branch to Treat Non-Small Cell Lung Cancer FDA Requirements for Approval of Drugs June 20, 1989 Do Do to Treat Superficial Bladder Cancer Format and Content of the Clinical and July 1, 1988 Do Drug Information Branch or Statistical Sections of New Drug Internet a http:// Applications* www.fda.gov/cder/guidance/ index.htm Format and Content of the Summary for February 1, 1987 Do Drug Information Branch New Drug and Antibiotic Applications* Formatting, Assembling and Submitting February 1, 1987 Do Do New Drug and Antibiotic Applications* General Considerations for the December 1, 1978 Do Drug Information Branch Clinical Evaluation of Drugs (FDA 77- 3040) General Considerations for the N/A Do Drug Information Branch Clinical Evaluation of Drugs in Infants and Children (FDA 77-3041) Oncologic Drugs Advisory Committee April 13, 1988 Do Drug Information Branch Discussion on FDA Requirements for Approval of New Drugs for Treatment of Ovarian Cancer Oncologic Drugs Advisory Committee N/A Do Do Discussion on FDA Requirements for Approval of New Drugs for Treatment of Colon and Rectal Cancer OTC Treatment of Hypercholesterolemia October 27, 1997 Do Drug Information Branch or (CLIN 5) Internet at http:// www.fda.gov/cder/guidance/ index.htm Points to Consider in the Clinical October 26, 1992 Do Drug Information Branch Development and Labeling of Anti- Infective Drug Products Points to Consider in the Preclinical November 1, 1990 Do Do Development of Antiviral Drugs Points to Consider in the Preclinical May 1, 1993 Do Do Development of Immunomodulatory Drugs for the Treatment of HIV Infection and Associated Disorders Points to Consider: Clinical September 19, 1994 Do Do Development Programs for MDI and DPI Drug Products Postmarketing Adverse Experience August 27, 1997 Do Drug Information Branch or Reporting for Human Drugs and Internet at http:// Licensed Biological Products; www.fda.gov/cder/guidance/ Clarification of What to Report (CLIN index.htm 4) Postmarketing Reporting of Adverse March 1, 1992 Do Drug Information Branch Drug Experiences (85D-0249) Preparation of Investigational New March 1, 1991 Do Drug Information Branch Drug Products (Human and Animal) [[Page 9828]] Study and Evaluation of Gender July 22, 1993 Do Do Differences in the Clinical Evaluation of Drugs Study of Drugs Likely to be Used in November 1, 1989 Do Do the Elderly Computerized Systems Used in Clinical June 18, 1997 Compliance (Draft) Drug Information Branch or Trials Internet at http:// www.fda.gov/cder/guidance/ index.htm Manufacture, Processing or Holding of September 20, 1996 Do Do Active Pharmaceutical Ingredients Repackaging of Solid Oral Dosage Form February 1, 1992 Do Drug Information Branch Drug Products (92D-0345) Supplements to New Applications, December 12, 1994 Do Drug Information Branch Abbreviated New Drug Applications or Abbreviated Antibiotic Applications for Nonsterile Drug Products (93D- 0403) A Review of FDA's Implementation of N/A Compliance Drug Information Branch the Drug Export Amendments of 1986 Compressed Medical Gases December 1, 1989 Do Do Current Good Manufacturing Practices April 22, 1997 Do Drug Information Branch or for Positron Emission Tomographic Internet at http:// (PET) Drug Products (CP 1) www.fda.gov/cder/guidance/ index.htm Expiration Dating and Stability June 27, 1997 Do Drug Information Branch or Testing of Solid Oral Dosage Form Internet at http:// Drugs Containing Iron (CP 2) www.fda.gov/cder/guidance/ index.htm General Principles of Process May 1, 1987 Do Drug Information Branch or Validation Internet at http:// www.fda.gov/cder/guidance/ index.htm Good Laboratory Practice Regulations N/A Do Drug Information Branch Questions and Answers Monitoring of Clinical Investigations January 1, 1988 Do Do Nuclear Pharmacy Guideline Criteria May 1, 1984 Do Do for Determining When to Register as a Drug Establishment Sterile Drug Products Produced by May 1, 1987 Do Do Aseptic Processing Validation of Limulus Amebocyte Lysate December 1, 1987 Do Do Test as an End-Product Endotoxin Test for Human and Animal Parenteral Drugs, Biological Products, and Medical Devices Content and Format of an Abbreviated April 18, 1997 Generic Drug (Draft) Drug Information Branch or New Drug Application (ANDA)--Positron Internet at http:// Emission Tomography (PET) Drug www.fda.gov/cder/guidance/ Products_With Specific Information index.htm for ANDAs for Fludeoxyglucose F18 Injection Letter announcing that the OGD will August 18, 1995 Generic Drug Drug Information Branch now accept the ICH long-term storage conditions as well as the stability studies conducted in the past. Letter describing efforts by the CDER October 14, 1994 Do Do and the ORA to clarify the responsibilities of CDER chemistry review scientists and ORA field investigators in the new and abbreviated drug approval process in order to reduce duplication or redundancy Letter on incomplete Abbreviated April 8, 1994 Do Do Applications, Convictions Under GDEA, Multiple Supplements, Annual Reports for Bulk Antibiotics, Batch Size for Transdermal Drugs, Bioequivalence Protocols, Research, Deviations from OGD Policy Letter on the provision of new July 1, 1992 Do Do information pertaining to new bioequivalence guidelines and refuse- to-file letters Letter on the provision of new March 15, 1989 Do Do procedures and policies affecting the generic drug review process Letter on the request for cooperation November 8, 1991 Do Do of regulated industry to improve the efficiency and effectiveness of the generic drug review process, by assuring the completeness and accuracy of required information and data submissions Letter on the response to 12/20/84 March 26, 1985 Do Do letter from the Pharmaceutical Manufacturers Association about the Drug Price Competition and Patent Term Restoration Act [[Page 9829]] Letter to all ANDA and AADA applicants January 15, 1993 Do Do about the Generic Drug Enforcement Act of 1992 (GDEA), and the Office of Generic Drugs intention to refuse-to- file incomplete submissions as required by the new law Letter to regulated industry notifying August 4, 1993 Do Do interested parties about important detailed information regarding labeling, scale-up, packaging, minor/ major amendment criteria, and bioequivalence requirements Organization of an Abbreviated New April 7, 1997 Do Drug Information Branch or Drug Application and an Abbreviated Internet at http:// Antibiotic Application (OGD 1) www.fda.gov/cder/guidance/ index.htm Positron Emission Tomography Questions October 24, 1996 Do Drug Information Branch or and Answers 1 Internet at http:// www.fda.gov/cder/guidance/ index.htm Positron Emission Tomography Questions April 18, 1997 Do Do and Answers 2 A Revision in Sample Collection Under July 15, 1996 Industry letters Drug Information Branch the Compliance Program Pertaining to Pre-Approval Inspections Certification Requirements for July 27, 1992 Do Do Debarred Individuals in Drug Applications Continuation of a series of letters June 1, 1990 Do Do communicating interim and informal generic drug policy and guidance. Availability of Policy and Procedure Guides, and further operational changes to the generic drug review program Fifth of a series of letters providing April 10, 1987 Do Do informal notice about the Act, discussing the statutory mechanism by which ANDA applicants may make modifications in approved drugs where clinical data is required Fourth of a series of letters October 31, 1986 Do Do providing informal notice to all affected parties about policy developments and interpretations regarding the Act. Three year exclusivity provisions of Title I Implementation of the Drug Price October 11, 1984 Do Do Competition and Patent Term Restoration Act. Preliminary Guidance Implementation Plan USP injection October 2, 1995 Do Do nomenclature In Vivo Bioequivalence Studies of April 22, 1996 Do Do Clozapine Instructions for Filing Supplements April 11, 1996 Do Do Under the Provisions of SUPAC-IR Seventh of a series of letters about July 29, 1988 Do Do the Act providing guidance on the ``180-day exclusivity'' provision of section 505(j)(4)(B)(iv) of the FD&C Sixth of a series of informal notice April 28, 1988 Do Do letters about the Act discussing 3- and 5-year exclusivity provisions of sections 505(c)(3)(D) and 505(j)(4)(D) of the FD&C Act Streamlining Initiatives December 24, 1996 Do Do Supplement to 10/11/84 letter about November 16, 1984 Do Do policies, procedures and implementation of the Act (Q & A format) Third of a series of letters regarding May 1, 1985 Do Do the implementation of the Act Archiving Submissions in Electronic September 23, 1997 Information Drug Information Branch or Format--NDAs (IT 1) Technology Internet at http:// www.fda.gov/cder/guidance/ index.htm CANDA (Computer Assisted New Drug October 1, 1994 Do Drug Information Branch Application) Guidance Manual (92D- 0296) Acetaminophen and Codeine Phosphate December 1, 1993 Labeling Drug Information Branch Oral Solution/Suspension Acetaminophen and Codeine Phosphate December 1, 1993 Do Do Tablets/Capsules Acetaminophen, Aspirin and Codeine December 1, 1993 Do Drug Information Branch or Phosphate Tablets/Capsules Internet at http:// www.fda.gov/cder/guidance/ index.htm Alprazolam Tablets May 1, 1993 Do Do [[Page 9830]] Amiloride Hydrochloride and October 1, 1992 Do Do Hydrochlorothiazide Tablets USP Amlodipine Besylate Tablets (OGD-L-1) September 1, 1997 Do Do Antihistamine Guidance April 1, 1983 Do Drug Information Branch Astemizole Tablets (OGD-L-16) September 1, 1997 Do Do Atenolol Tablets June 1, 1995 Do Drug Information Branch or Internet at http:// www.fda.gov/cder/guidance/ index.htm Barbiturate, Single Entity-Class March 1, 1981 Do Drug Information Branch Labeling Butalbital, Acetaminophen and Caffeine April 1, 1993 Do Drug Information Branch or Capsules/Tablets Internet at http:// www.fda.gov/cder/guidance/ index.htm Butalbital, Acetaminophen, Caffeine September 21, 1997 Do Drug Information Branch and Hydocodone Bitartrate Tablets (OGD-L-6-R1) Butorphanol Tartrate Injection USP October 1, 1992 Do Drug Information Branch or Internet at http:// www.fda.gov/cder/guidance/ index.htm Captopril and Hydrochlorothiazide April 1, 1995 Do Do Tablets Captopril Tablets February 1, 1995 Do Drug Information Branch Carbidopa and Levodopa Tablets February 1, 1992 Do Drug Information Branch or Internet at http:// www.fda.gov/cder/guidance/ index.htm Chlordiazepoxide Hydrochloride January 1, 1988 Do Drug Information Branch Capsules Cimetidine Hydrochloride Injection September 1, 1995 Do Drug Information Branch or Internet at http:// www.fda.gov/cder/guidance/ index.htm Cimetidine Tablets September 1, 1995 Do Do Cisapride Oral Suspension (OGD-L-3) September 1, 1997 Do Do Cisapride Tablets (OGD-L-4) September 1, 1997 Do Do Clindamycin Phosphate Injection USP May 1, 1992 Do Do Clorazepate Dipotassium Capsules/ March 1, 1993 Do Drug Information Branch Tablets Combination Oral Contraceptives-- January 1, 1994 Do Do Physician and Patient Labeling Cyproheptadine Hydrochloride Tablets/ December 1, 1986 Do Do Syrup Diclofenac Sodium Delayed-Release February 1, 1995 Do Drug Information Branch or Tablets Internet at http:// www.fda.gov/cder/guidance/ index.htm Diltiazem Hydrochloride Extended- September 1, 1995 Do Do Release Capsules (twice a day dosage) Diphenoxylate Hydrochloride and April 1, 1995 Do Do Atropine Sulfate Oral Solution Diphenoxylate Hydrochloride and April 1, 1995 Do Do Atropine Sulfate Tablets Dipivefrin Hydrochloride Ophthalmic May 1, 1992 Do Drug Information Branch Solution, 0.1% Ergoloid Mesylates Tablets January 1, 1988 Do Do Estrogen Class Labeling Guidance August 1, 1992 Do Do Fludeoxyglucose F18 Injection January 1, 1997 Do Drug Information Branch or Internet at http:// www.fda.gov/cder/guidance/ index.htm Flurbiprofen Tablets USP January 1, 1994 Do Do Fluroxamine Maleate Tablets (OGD-L-15) September 1, 1997 Do Do Gentamicin Sulfate Ophthalmic Ointment April 1, 1992 Do Do and Solution Heparin Sodium Injection USP March 1, 1991 Do Do Hydrocodone Bitartrate and April 1, 1994 Do Do Acetaminophen Tablets Hydroxyzine Hydrochloride Injection December 1, 1989 Do Drug Information Branch Hydroxyzine Hydrochloride Tablets/ May 1, 1986 Do Do Syrup Hypoglycemic Oral Agents--Federal April 1, 1984 Do Do Register Indomethacin Capsules USP September 1, 1995 Do Drug Information Branch or Internet at http:// www.fda.gov/cder/guidance/ index.htm Informal Labeling Guidance Texts for December 1, 1992 Do Drug Information Branch Estrogen Drug Products--Patient Labeling Informal Labeling Guidance Texts for December 1, 1992 Do Do Estrogen Drug Products--Professional Labeling Isoetharine Inhalation Solution March 1, 1989 Do Do Leucovorin Calcium for Injection N/A Do Drug Information Branch or Internet at http:// www.fda.gov/cder/guidance/ index.htm Leucovorin Calcium Tablets, USP July 1, 1996 Do Drug Information Branch [[Page 9831]] Local Anesthetics--Class Labeling September 1, 1982 Do Do Meclofenamate Sodium Capsules July 1, 1992 Do Do Medroxy-progesterone Acetate Tablets, November 1, 1997 Do Do USP OGD-L-36 Metaproterenol Sulfate Inhalation May 1, 1992 Do Drug Information Branch or Solution, 5% Internet at http:// www.fda.gov/cder/guidance/ index.htm Metaproterenol Sulfate Syrup May 1, 1992 Do Do Metaproterenol Sulfate Tablets May 1, 1992 Do Do Metoclopramide Tablets USP/Oral February 1, 1995 Do Do Solution Naphazoline Hydrochloride Ophthalmic March 1, 1989 Do Drug Information Branch Solution Naproxen Sodium Tablets, USP OGD-L-10- September 1, 1997 Do Drug Information Branch or R1 Internet at http:// www.fda.gov/cder/guidance/ index.htm Naproxen Tablets, USP OGD-L-9-R1 September 1, 1997 Do Do Niacin Tablets July 1, 1992 Do Drug Information Branch Paclitaxel Injection OGD-L-8 September 1, 1997 Do Do Phendimetrazine Tartrate Capsules/ February 1, 1991 Do Do Tablets, and Extended-Release Capsules Phentermine Hydrochloride Capsules/ August 1, 1988 Do Do Tablets Promethazine Hydrochloride Tablets March 1, 1990 Do Do Propantheline Bromide Tablets August 1, 1988 Do Do Pyridoxine Hydrochloride Injection June 1, 1984 Do Do Quinidine Sulfate Tablets/Capsules October 1, 1995 Do Do Ranitidine Tablets November 1, 1993 Do Drug Information Branch or Internet at http:// www.fda.gov/cder/guidance/ index.htm Risperidone Oral Solution OGD-L-18 September 1, 1997 Do Do Risperidone Tablets OGD-L-17 September 1, 1997 Do Do Sulfacetamide Sodium and Prednisolone January 1, 1995 Do Do Acetate Ophthalmic Suspension and Solution Sulfacetamide Sodium Ophthalmic August 1, 1992 Do Do Solution/Ointment Sulfamethoxazole and Phenazopyridine February 1, 1992 Do Drug Information Branch Hydrochloride Tablets Sulfamethoxazole and Trimethoprim August 1, 1993 Do Drug Information Branch or Tablets and Oral Suspension Internet at http:// www.fda.gov/cder/guidance/ index.htm Theophylline Immediate-Release Dosage February 1, 1995 Do Drug Information Branch Forms Theophylline Intravenous Dosage Forms February 9, 1996 Do Do Thiamine Hydrochloride Injection February 1, 1988 Do Do Tobramycin Sulfate Injection May 1, 1993 Do Drug Information Branch Internet at http:// www.fda.gov/cder/guidance/ index.htm Topical Corticosteroids Class Labeling N/A Do Drug Information Branch Venlafaxine Hydrochloride Tablets OGD- October 1, 1997 Do Do L-30 Verapamil Hydrochloride Tablets October 1, 1991 Do Drug Information Branch or Internet at http:// www.fda.gov/cder/guidance/ index.htm Vitamin A Capsules February 1, 1992 Do Drug Information Branch Zolpidem Tartrate Tablets OGD-L-13 September 1, 1997 Do Do Points to Consider for OTC Actual Use July 22, 1994 OTC (Draft) Do Studies Enforcement Policy on Marketing OTC N/A OTC Do Combination Products (CPG 7132b.16) General Guidelines for OTC Combination N/A Do Do Products (78D-0322) OTC Nicotine Sustitutes March 1, 1994 Do Drug Information Branch Upgrading Category III Antiperspirants N/A Do Do to Category I (43 FR 46728-46731) Format and Content of the Nonclinical February 1, 1987 Pharmacology/ Do Pharmacology/Toxicology Section of an Toxicology Application* Points to Consider in the Nonclinical N/A Do Drug Information Branch or Pharmacology/Toxicology Development Internet at http:// of Topical Drugs Intended to Prevent www.fda.gov/cder/guidance/ the Transmission of Sexually index.htm Transmitted Diseases (STD) and/or for the Development of Drugs Intended to Act as Vaginal Contraceptives [[Page 9832]] Reference Guide for the Nonclinical February 1, 1989 Do Drug Information Branch Toxicity Studies of Antiviral Drugs (REMOVE) Indicated for the Treatment of Non- Life Threatening Disease: Evaluation of Drug Toxicity Prior to Phase I Clinical Studies ---------------------------------------------------------------------------------------------------------------- \1\ Star (*) indicates that the guidance is one of 13, formerly known as the ``NDA Guidelines,'' or ``Rainbow Pack,'' that are available as a set from the Drug Information Branch. V. Guidance Documents Issued by the Center for Food Safety and Applied Nutrition (CFSAN) ---------------------------------------------------------------------------------------------------------------- How to Obtain a Hard Copy of Grouped by Intended the Document (Name and Name of Document Date of Issuance User or Regulatory Address, Phone, FAX, E-mail, Activity or Internet) ---------------------------------------------------------------------------------------------------------------- Compliance Policy Guides Manual, PB96- 1996 FDA Regulated National Technical 920500 Industries Information Service (NTIS), 5285 Port Royal Rd., Springfield, VA 22161 Compliance Programs Guidance Manual, 1995 Do NTIS PB95-915499 FDA Recall Policy 1995 Do Industry Activities Staff (HFS-565), Center for Food Safety and Applied Nutrition, Food and Drug Administration, 200 C St. SW., Washington, DC 20204 Inspection Operations Manual, PB-95- October 1994 Do NTIS 913399 Regulatory Procedures Manual, PB95- August 1995 Do NTIS 265534 Requirements of Laws and Regulations 1997 Do Superintendent of Documents, Enforced by the U.S. Food and Drug Government Printing Office, Administration ``Blue Book'' Washington, DC 20402 Action Levels for Poisonous or 1995 Food and Animal Feed Industry Activities Staff Deleterious Substances in Human Food Industries and Animal Feed, PB96-920500 Pesticides Analytical Manual, PB94- 1994 Food Industry NTIS 911899 FDA Advisory for Deoxynivanol (DON) in September 16, 1993 Food and Animal Feed Office of Plant and Dairy Finished Wheat Products Intended for Industries Foods and Beverages, Food Human Consumption and in Grain and and Drug Administration (HFS- Grain By-Products for Animal Feed 306), 200 C St. SW., Washington, DC 20204, 202- 205-4681 FDA's Cosmetic Labeling Manual October 1991 Cosmetic Industry Office of Colors and Cosmetics (HFS-105), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-205-4493 Statement of Policy: Foods Derived May 29, 1992 (57 Developers of New Office of Premarket Approval, from New Plant Varieties: Notice FR 22984) Plant Food Varieties Food and Drug Administration (HFS-200), 200 C St. SW., Washington, DC 20204, 202- 418-3100 A Food Labeling Guide September 1994 Food Industry Superintendent of Documents, Appendix I--Model Small Business Food August 7, 1993 Do Industry Activities Staff Labeling Exemption Notice Food Labeling: Questions and Answers August 1993 Do Industry Activities Staff Food Labeling: Questions and Answers: August 1995 Do Superintendent of Documents Volume II Fair Packaging and Labeling Act June 1978 Do NTIS Requirements and Interpretations, PB- 83-222117 Bacteriological Analytical Manual, 7th 1992 FDA Regulated AOAC International, 481 N. Edition Industries Frederick Ave., Suite 500, Gaithersburg, MD 20877-2417, 301-924-7077 FDA Food Importer's Guide for Low-Acid 1995 Food Industry Industry Activities Staff Canned and Acidified Foods Fabrication of Single Service 1995 States Milk Safety Branch (HFS-626), Containers and Closures for Milk and Center for Food Safety and Milk Products Applied Nutrition, 200 C St. SW., Washington, DC 20204, 202-205-9175 Evaluation of Milk Laboratories 1995 Do Do Methods of Making Sanitation Ratings 1995 Do Do Of Milk Supplies [[Page 9833]] Dry Milk Ordinance 1995 Do Do Procedures Governing the Cooperative 1995 Dairy Industry Do State-Public Health Service/Food and Drug Administration Program for Certification of Interstate Milk Shippers Frozen Dessert Processing Guidelines 1989 Do Office of Plant and Dairy Foods and Beverages (HFS- 302), Center for Food Safety and Applied Nutrition, 200 C St. SW., Washington, DC 20204, 202-205-9175 Pasteurized Milk Ordinance 1995 States Milk Safety Branch FDA Nutrition Labeling Manual: A Guide 1993 Food Industry Office of Food Labeling, Food for Developing and Using Databases and Drug Administration (HFS- 150), 200 C St. SW., Washington, DC 20204, 202- 205-4561 Guidelines for Determining Metric October 1, 1993 Do Do Equivalents of Household Measures List of Food Defect Action Levels 1995 Food and Animal Feed Industry Activities Staff (DALS) Industries Action Levels for Poisonous or 1995 Do Do Deleterious Substances in Human Food and Feed (Also Found in CPG's) 1997 FDA Food Code 1997 States NTIS Seafood List 1993 Seafood Industry Superintendent of Documents Manual of Operations National 1992 States Office of Seafood (HFS-407), Shellfish Sanitation Shellfish Sanitation Branch, 200 C St. SW., Washington, DC 20204, 202-418-3150 Fish and Fisheries Products Hazards 1996 Seafood Industry Office of Seafood, Food and and Controls Guide Drug Administration (HFS- 400), 200 C St. SW., Washington, DC 20204, 202- 418-3150 Guidance for Submitting Requests under 1996 Food Packaging Office of Premarket Approval 21 CFR 170.39, Threshold of Industry Regulation for Substances Used in Food Articles Guidelines for the Preparation of 1996 Food Ingredient or Do Petition Submissions Packaging Industry Guidelines for Approval of Color 1996 Color or Contact Lens Do Additives in Contact Lenses Intended Industry as Colors FDA Recommendations for Submission of February 1993 Color Additives Do Chemical and Technological Data on Industry Color Additives for Food, Drugs or Cosmetics Use Points to Consider for the Use of December 1992 Food Packaging Do Recycled Plastics in Food Packaging: Industry Chemistry Considerations Recommendations for Submission of May 1993 Do Do Chemical and Technological Data for Direct Food Additive and GRAS Food Ingredient Petitions Recommendations for Chemistry Data for June 1995 Do Do Indirect Food Additive Petitions Enzyme Preparations: Chemistry January 1993 Food Enzyme Industry Do Recommendations for Food Additive and GRAS Affirmation Petitions Estimating Exposure to Direct Food September 1995 Food and Food Office of Premarket Approval Additive and Chemical Contaminants in Ingredient Industry the Diet Toxicological Principles for the 1982 Petitioners for Food NTIS Safety Assessment of Direct Food or Color Additives Additives and Color Additives Used in Food (also known as Redbook I), PR-83- 170696 Environmental Assessment Technical March 1987 Do Do Handbook, PB87175345-AS, A-01 Preparing Environmental Assessments: August 1990 Do Office of Premarket Approval General Suggestions Step-by-Step Guidance for Preparing March 1987 Do Do Environmental Assessments Environmental Assessment of Food- February 1994 Do Do packaging Materials with Enhanced Degradation Characteristics Color Additive Petitions Information 1996 Petitioners for Color Do and Guidance Additives Toxological Testing of Food Additives 1983 Petitioners for Food Do or Color Additives List of Products for Each Product October 8, 1992 Food Industry Office of Food Labeling Category [[Page 9834]] Label Declaration of Allergenic June 10, 1996 Do Do Substances in Foods; Notice to Manufacturers Guidance on Labeling of Foods that February 24, 1997 Do Do Need Refrigeration by Consumers (62 FR 8248) Interim Guidance on the Voluntary February 10, 1994 Do Do Labeling of Milk and Milk Products (59 FR 6279) that have not been treated with Recombinant Bovine Somatropin Guidelines Concerning Notification and 1985 Infant Formula Office of Special Testing of Infant Formula Manufacturers Nutritionals (HFS-450), Food and Drug Administration, 200 C St. SW., Washington, DC 20204 Clinical Testing of Infant Formulas 1985 Do Do with Respect to Nutritional Suitability for Term Infants Guidelines for the Evaluation of the 1988 Do Do Safety and Suitability of New Infant Formulas for Feeding Infants with Allergic Diseases Guidelines for the Evaluation of the 1990 Do Do Safety and Suitability of Infant Formulas for Feeding Infants with Allergic Diseases Guidelines for the Clinical Evaluation 1987 Do Do of New Products Used in the Dietary Management of Infants, Children and Pregnant Women with Metabolic Disorders Guidance Document for Arsenic (Trace January 1993 States Office of Seafood (HFS-400) Elements in Seafood) or via Internet: FDA Home Page at http:// vm.cfsan.fda.gov/list.html Guidance Document for Cadmium (Trace January 1993 Do Office of Seafood (HFS-400) Elements in Seafood) or via Internet: FDA Home Page at http:// vm.cfsan.fda.gov Guidance Document for Chromium (Trace January 1993 Do Do Elements in Seafood) Guidance Document for Lead (Trace August 1993 Do Do Elements in Seafood) Guidance Document for Nickel (Trace January 1993 Do Do Elements in Seafood) FDA's Policy for Foods Developed by 1995 Food Industry Office of Premarket Approval Biotechnology or via Internet: FDA Home Page at http:// vm.cfsan.fda.gov Bovine Spongiform Encephalopathy (BSE) 1997 Do Office of Plant and Dairy In Products for Human Use Foods and Beverages or via Internet: FDA Home Page at http://www.fda.gov/opacom/ morechoices/industry/ guidance/gelguide.htm Shellfish Sanitation Model Ordinance 1995 States Shellfish Program Implementation Branch, Division of Cooperative Programs, Office of Field Programs (HFS-628), 200 C St. SW., Washington, DC 20204, 202-205-8137 ---------------------------------------------------------------------------------------------------------------- VI. Guidance Documents Issued by the Center for Veterinary Medicine (CVM) ---------------------------------------------------------------------------------------------------------------- How to Obtain a Hard Copy of Grouped by Intended the Document (Name and Name of Document Date of Issuance User or Regulatory Address, Phone, FAX, E-mail, Activity or Internet) ---------------------------------------------------------------------------------------------------------------- Citizen Petitions: Policy and June 7, 1994 Do Do Procedures (Guide No. 1240.2030) CVM's Implementation of the Agency's June 15, 1994 Do Do Fraud, Untrue Statements of Material Facts, Bribery & Illegal Gratuities Policy (Guide No. 1240.2040) Intra-Agency Relationship (Guide No. August 11, 1993 Do Do 1240.2100) Procedures for Resolving Disagreements April 10, 1991 Do Do within CVM (Guide No. 1240.2110) Product Manager (Guide No. 1240.2120) August 11, 1993 Do Do [[Page 9835]] CVM P & P Manual Utilization and September 3, 1997 Do Do Maintenance (Guide No. 1240.2140) CVM Small Business (Guide No. April 10, 1991 Do Do 1240.2150) CVM Public Affairs Program (Guide No. April 7, 1995 Do Do 1240.2152) Evaluation of Proposed Legislation April 7, 1995 Do Do (Guide No. 1240.2154) Voluntary Compliance (Guide No. August 11, 1992 Do Do 1240.2202) Approval of New Animal Drug August 11, 1992 Do Do Applications and their Supplements (Guide No. 1240.2210) Classification of OTC and Rx Drugs January 15, 1985 Do Do (Guide No. 1240.2220) Processing General Correspondence by June 28, 1993 Do Do Individual Offices in CVM (Guide No. 1240.2300) Routing of Congressional April 9, 1997 Do Do Correspondence (Guide No. 1240.2302) Correspondence to Practicing June 28, 1993 Do Do Veterinarians, Vet Med Associations, and other Scientific Disciplines (Guide No. 1240.2310) Communication and Liaison with other May 7, 1991 Do Do Centers and Agencies (Guide No. 1240.2320) Intercommunication between CVM and June 28, 1993 Do Do Office of Chief Counsel (Guide No. 1240.2322) CVM Guidance on Media Inquiries (Guide July 1, 1997 Do Do No. 1240.2325) Consultative Reviews and Opinions May 7, 1991 Do Do (Guide No. 1240.2330) Freedom of Information Requests (Guide September 4, 1997 Do Do No. 1240.2500) Public Availability of Food Additive June 25, 1993 Do Do Petitions (Guide No. 1240.2501) Advisory Opinions and Informal October 23, 1985 Do Do Requests for Information (Guide No. 1240.2510) Confidentiality of Center Files (Guide June 25, 1993 Do Do No. 1240.2520) Industry Conferences (Guide No. June 11, 1990 Do Do 1240.2600) Meetings with Representatives from September 8, 1994 Do Do Foreign Governments (Guide No. 1240.2601) Trade Media Visits to CVM (Guide No. September 8, 1994 Do Do 1240.2610) New Animal Drugs for Investigational September 30, 1996 Do Do Use (Guide No. 1240.3000) Processing Original Investigational September 30, 1996 Do Do New Animal Drug Applications (Guide No. 1240.3010) Processing Amendments to An September 30, 1996 Do Do Investigational New Animal Drug Application (Guide No. 1240.3020) Non-Routine Invest. New Animal Drugs September 30, 1996 Do Do (Guide No. 1240.3025) Initial Processing of an NADA (Guide March 25, 1991 Do Do No. 1240.3100) Review of Animal Safety and August 1, 1989 Do Do Effectiveness Data (Guide No. 1240.3101) Use of Foreign Non-Clinical and September 6, 1989 Do Do Clinical Data in an NADA (Guide No. 1240.3102) Review of Vet. Med. Guidelines (Guide November 23, 1993 Do Do No. 1240.3103) Specialty Reviews of NADAs (Guide No. December 17, 1993 Do Do 1240.3110) Preparation of NADA Decision Package November 23, 1993 Do Do (Guide No. 1240.3120) Routing of NADA Decision Package November 23, 1993 Do Do (Guide No. 1240.3122) CVM Appeals Procedure Guide (Guide No. November 23, 1993 Do Do 1240.3130) Animal Drug Applications Expedited November 23, 1993 Do Do Review Guideline (Guide No. 1240.3135) Labeling Policy for Animal Drugs that October 13, 1994 Do Do may be Human Carcinogens (Guide No. 1240.3140) NADA Review of Dosage Form Oral October 13, 1994 Do Do Electrolytes (Guide No. 1240.3150) Food Additive Petition Review (Guide December 7, 1993 Do Do No. 1240.3300) [[Page 9836]] Nutritional Ingredients in Animal March 23, 1993 Do Do Drugs and Feeds (Guide No. 1240.3420) New Animal Drug Determination (Guide July 24, 1989 Do Do No. 1240.3500) New Animal Drug Regulation (Guide No. September 4, 1991 Do Do 1240.3502) Drug Experience Reporting Requirements November 23, 1993 Do Do (Guide No. 1240.3510) Additional Sources of Adverse Reaction November 23, 1993 Do Do and Injury Reports (Guide No. 1240.3512) Drug Experience Reporting by May 7, 1997 Do Do Veterinarians (Guide No. 1240.3514) Adverse Reactions as a Basis for November 23, 1993 Do Do Regulatory Action (Guide No. 1240.3520) Animal Health Hazard Evaluation March 28, 1986 Do Do Committee (Guide No. 1240.3521) Review and Evaluation of Drug November 23, 1993 Do Do Experience Reports (Guide No. 1240.3522) Criteria for Veterinary Medical Review November 23, 1993 Do Do of Establishment Inspection Reports (Guide No. 1240.3524) Procedures for Processing Drug November 23, 1993 Do Do Experience Reports (Guide No. 1240.3530) Consumer Complaint Letters (Guide No. September 6, 1989 Do Do 1240.3532) NADAs, Withdrawal of Approvals (Guide November 23, 1993 Do Do No. 1240.3540) Implementation of Causal Reviews November 23, 1993 Do Do (Guide No. 1240.3542) Surveillance at Professional and Trade November 23, 1993 Do Do Meetings (Guide No. 1240.3550) Registration of Producers of Drugs and September 9, 1997 Do Do Listing Of Drugs in Commercial Distribution (Guide No. 1240.3560) Types of Enforcement Activities (Guide September 9, 1997 Do Do No. 1240.3600) Types of Regulatory Actions (Guide No. September 9, 1997 Do Do 1240.3601) Regulating Animal Foods with Drug September 9, 1997 Do Do Claims (Guide No. 1240.3605) Request for CGMP Establishment September 9, 1997 Do Do Inspections (Guide No. 1240.3620) Good Manufacturing Practice Compliance September 9, 1997 Do Do Status (Guide No. 1240.3622) Tissue Residue Reporting (Guide No. September 9, 1997 Do Do 1240.3630) Diversion of Unfit Food to Animal Use September 9, 1997 Do Do (Guide No. 1240.3650) Development of Compliance Policy September 9, 1997 Do Do Guides Affecting Veterinary Products (Guide No. 1240.3660) Preparation of Compliance Programs and September 9, 1997 Do Do Program Circulars (Guide No. 1240.3661) Management of Formal Evidentiary September 9, 1997 Do Do Hearings (Guide No. 1240.3670) Center for Veterinary Medicine November 3, 1993 Do Do Research Activities (Guide No. 1240.3700) Initiation and Approval of Research November 3, 1993 Do Do Projects (Guide No. 1240.3710) Identification/Promotion of NADA September 10, 1997 Do Do Product Approval (Guide No. 1240.4000) Procedure for Center Recommended September 10, 1997 Do Do Labeling Changes (Guide No. 1240.4005) Antibacterials Labeled for Secondary September 10, 1997 Do Do Infections (Guide No. 1240.4010) Uniformity in Labeling (Guide No. September 10, 1997 Do Do 1240.4020) General Policies for Animal Drug Label September 10, 1997 Do Do Review (Guide No. 1240.4021) Therapeutic Use Directions for September 10, 1997 Do Do Medicated Feed and Drinking Water (Guide No. 1240.4025) Established Names (Guide No. September 10, 1997 Do Do 1240.4030) Clinical Investigator Sanctions & the September 10, 1997 Do Do Videotex Method of Obtaining Information on Ineligible Investigators (Guide No. 1240.4040) Criteria for the Approval of January 5, 1987 Do Do Euthanasia Products (Guide No. 1240.4112) [[Page 9837]] Sterility of Ophthalmic Products December 7, 1993 Do Do (Guide No. 1240.4120) Sterility and Pyrogen Requirements for November 27, 1989 Do Do Injectable Drug Products (Guide No. 1240.4122) Overformulation in Animal Drug January 2, 1992 Do Do Products (Guide No. 1240.4130) Continuous Use Production Drugs & April 16, 1990 Do Do Short-Term Therapeutic Treatments in Feeds (Guide No. 1240.4145) Ownership Transfer or Corporate January 2, 1992 Do Do Identity Change of an Application (Guide No. 1240.4150) Policy on Sterilization of New Animal September 10, 1997 Do Do Drug Products and Containers by Irradiation (Guide No. 1240.4160) CVM Medically Necessary Veterinary June 30, 1994 Do Do Drug Product Shortage Management (Guide No. 1240.4170) Drug Use in Aquaculture Enforcement October 29, 1997 Do Do Priorities (Guide No. 1240.4200) Extra-label Use of Approved Drugs in October 29, 1997 Do Do Aquaculture (Guide No. 1240.4210) Drug-Pesticide Issues (Guide No. October 29, 1997 Do Do 1240.4220) Regulation of Fish Identification October 29, 1997 Do Do Products (Guide No. 1240.4230) Safe Levels of Unapproved Drugs in October 29, 1997 Do Do Aquaculture (Guide No. 1240.4240) Classification of Aquaculture Species/ October 29, 1997 Do Do Population as Food or Non-Food (Guide No. 1240.4260) Use of Drugs in Outdoor Aquatic October 29, 1997 Do Do Research Facilities (Guide No. 1240.4270) Generic Animal Drug and Patent Term November 23, 1988 Animal drug industry Communications Staff (HFV- Restoration Act (GADPTRA) Policy 12), FDA/CVM, 7500 Standish Letter 1.--Describes patent and Pl., Rockville, MD 20855, exclusivity information to be 301-594-1755, FAX 301-594- submitted to FDA by holders of 1831 approved NADAs and NADA applicants GADPTRA Policy Letter 2.--Describes June 7, 1989 Do Do format and content for suitability petitions, format and content for ANADAs, manufacturing requirements for ANADAs, and environmental review of generic animal drugs GADPTRA Policy Letter 3.-- July 2, 1989 Do Do ``Exclusivity for human food safety data submitted in supplemental application,'' ``Withdrawal period for generic drugs,'' ``Substitution of an active ingredient in a combination drug or in a feed use combination,'' ``Labeling Requirements for Generic Drugs,'' ``Can a generic animal drug sponsor obtain exclusivity for an innovation approved under a supplement to an ANADA and can the pioneer drug sponsor copy the generic innovation without submitting additional data?'' GADPTRA Policy Letter 4.--``Actions November 2, 1989 Do Do concerning ANADAs when a pioneer drug has been withdrawn from sale,'' ``Effect of GADPTRA on approval of pre-62 drugs under the DESI program,'' ``Generic feed use combination drugs'' GADPTRA Policy Letter 5.-- April 12, 1990 Do Do Bioequivalence Guideline GADPTRA Policy Letter 6.--``Withdrawal October 17, 1990 Do Do period for generic animal drug products,'' ``Eligibiliity of a new salt or ester for a pioneer animal drug'' GADPTRA Policy Letter 7.--``Guidance March 20, 1991 Do Do for analytical methods for ANADAs,'' ``ANADAs, NADAs and supplemental approvals for subtherapeutic antibiotics,'' ``Hybrid applications,'' ``Waivers of In Vivo bioequivalence studies for topical products'' GADPTRA Policy Letter 8.--Generic July 23,1991 Do Do copying of certain drugs that were subject to review under the Drug Efficacy Study Implementation (DESI) program [[Page 9838]] GADPTRA Policy Letter 9.--``Policy June 27, 1995 Do Do Statement on Environmental Review of Generic Animal Drugs'' (Revision of a policy statement of the same title in Generic Policy Letter #2 Guide for Reporting Drug Shipment(s) June 19, 1992 Do Do for Clinical Trials in Non-Food Animals Guide for Reporting The Details of no date Do Do Clinical Trials Using Investigational New Animal Drug(s) in Food-Producing Animals Aquaculture Drug Use: Answers to June 1995 Do Do Internet via http:// Commonly Asked Questions www.cvm.fda.gov/ Guideline 3.--General Principles for July 1994 Do Do Evaluating the Safety of Compounds Used in Food-Producing Animals Guideline 4.--Guidelines for Efficacy no date Do Do Studies for Systemic Sustained Release Sulfonamide Boluses for Cattle Guideline 5.--Stability Guidelines December 1990 Do Do Guideline 6.--Guidelines for March 1976 Do Do Submitting NADA's for Generic Drugs Reviewed by NAS/NRC Guideline 9.--Preclearance Guidelines October 1975 Do Communications Staff for Production Drugs Guideline 10.--Amendment of Section October 1975 Do Do Internet at http:// II(G)(1)(b)(4) of the Preclearance www.cvm.fda.gov/ Guidelines Guideline 13.--Guidelines for January 1985 Do Do Evaluation of Effectiveness of New Animal Drugs for Use in Free-Choice Feeds (revision of Medicated Block) Guideline 14.--Guideline and Format no date Do Do for Reporting the Details of Clinical Trials Using An Investigational New Animal Drug in FOOD Producing Animals Guideline 15.--Guideline and Format February 1977 Do Do for Reporting the Details of Clinical Trials Using An Investigational New Animal Drug in NON-FOOD Producing Animals Guideline 16.--FOI Summary Guideline May 1985 Do Do Guideline 18.--Antibacterial Drugs in no date Do Do Animal Feeds: Human Health Safety Criteria Guideline 19.--Antibacterial Drugs in no date Do Do Animal Feeds: Animal Health Safety Criteria Guideline 20.--Antibacterial Drugs in no date Do Do Animal Feeds: Antibacterial Effectiveness Criteria Guideline 22.--Guideline Labeling of no date Do Do Arecoline Base Drugs Intended for Animal Use Guideline 23.--Medicated Free Choice July 1985 Do Do Feeds--Manufacturing Control Guideline 24.----Guidelines for Drug October 1983 Do Do Combinations for Use in Animals Guideline 25.--Guidelines for the January 1979 Do Do Efficacy Evaluation of Equine Anthelmintics Guideline 26.--Guidelines for the April 1986 Do Do Preparation of Data to Satisfy the Requirements of Section 512 of the Act Regarding Animal Safety, Effectiveness, Human Food Safety and Environmental Considerations for Minor Use of New Animal Drugs Guideline 29.--Guidelines for the September 1980 Do Do Effectiveness Evaluation of Swine Anthelmintics Guideline 31.--Guidelines for the July 1981 Do Do Evaluation of Bovine Anthelmintics Guideline 33.--Target Animal Safety June 1989 Do Do Guidelines for New Animal Drugs Guideline 35.--Bioequivalence 1996 Do Do Guideline--Final (1996) Guideline 36.--Guidelines for Efficacy July 1985 Do Do Evaluation of Canine/Feline Anthelmintics Guideline 37.--Guidelines for March 1984 Do Do Evaluation of Effectiveness of New Animal Drugs for Use in Poultry Feed for Pigmentation Guideline 38.--Guideline for August 1984 Do Do Effectiveness Evaluation of Topical/ Otic Animal Drugs [[Page 9839]] Guideline 40.--Draft Guideline for the April 1992 Do Do Evaluation of the Efficacy of Anticoccidial Drugs and Anticoccidial Drug Combinations in Poultry Guideline 41.--Draft Guideline: June 1992 Do Do Formatting, Assembling, and Submitting New Animal Drug Applications Guideline 42.--Series of four 1994 Do Do guidelines entitled ``Animal Drug Manufacturing Guidelines, 1994'' Guideline 43.--Guidance on Generic October 1995 Do Do Animal Drug Products Containing Fermentation-Derived Drug Substances Guideline 45.--Guideline for Uniform August 1993 Do Do Labeling of Drugs for Dairy and Beef Cattle Guideline 48.--Guidance for Industry November 1994 Do Communications Staff for the Submission of Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products Guideline 49.--Guidance Document for April 1996 Do Do Target Animal Safety and Drug Effectiveness Studies for Anti- Microbial Bovine Mastitis Products Guideline 50.--Draft Guideline for February 1993 Do Do Target Animal and Human Food Safety, Drug Efficacy, Environmental and Manufacturing Studies for Teat Antiseptic Products Guideline 51.--Points to Consider 1993 Do Do Guideline--Development of a Pharmacokinetic Guideline Enabling Flexible Labeling of Therapeutic Antimicrobials Guideline 52.--Guidance-- January 1996 Do Do Microbiological Testing of Antimicrobial Drug Residues in Food Guideline 53.--Guideline for the May 1994 Do Do Evaluation of the Utility of Food Additives in Diets Fed to Aquatic Animals Guideline 54.--Draft Guideline for June 1994 Do Do Utility Studies for Anti-Salmonella Chemical Food Additives in Animal Feeds Guideline 55.--Supportive Data for Cat June 1994 Do Do Food Labels Bearing ``Reduces Urinary pH Claims: Guideline in Protocol Development'' Guideline 56.--Protocol Development November 1994 Do Do Guideline for Clinical Effectiveness and Target Animal Safety Trials Guideline 57.--Master Files--Guidance July 1995 Do Do for Industry for the Preparation and Submission of Veterinary Master Files Guideline 58.--Guidance for Industry May 1997 Do Do for Good Target Animal Study Practices: Clinical Investigators and Monitors Guideline 59.--Guidance to Industry June 1997 Do Do Submitting Notices of Claimed Investigational Exemption in Electronic Format to CVM Via E-mail Guideline 60.--Guidance for Industry June 1997 Do Do Animal Proteins Prohibited From Animal Feed, Small Entity Compliance Guide Guideline 61.--Draft Guidance for September 1997 Do Do Industry--FDA Approval of Animal Drugs for Minor Uses and for Minor Species Guideline 62.--Draft Guidance for August 1997 Do Do Industry--Consumer-Directed Broadcast Advertisements NADA Pre-approval Inspections (No. November 1, 1993 FDA investigators and Freedom of Information Staff 7368.001) analysts and (HFI-35), Food and Drug regulated industry Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-6310, FAX 301-443- 1726 Drug Process and New Animal Drug October 8, 1996 Do Do Inspections (No. 7371.001) Illegal Sales of Veterinary August 17, 1993 Do Do Prescription Drugs (No. 7371.002) Feed Contaminants (No. 7371.003) November 1, 1993 Do Do (July 31, 1996-- Partial Revision) Medicated Feeds (No. 7371.004) July 7, 1995 Do Do [[Page 9840]] Type A Medicated Articles (No. January 1, 1992 Do Do 7371.005) Illegal Drug Residues in Meat and September 9, 1996 Do Do Poultry (No. 7371.006) Imported Bulk New Animal Drugs (No. October 1, 1991 Do Do 7371.007) Center for Veterinary Medicine Public May 3, 1996 Do Do Affairs Specialist Program (No. 7371.826) CVM Initiates Veterinary Drug Listing February 3, 1994 Public information Communications Staff, FDA/ Verification CVM, 7500 Standish Pl. (HFV- 12), Rockville, MD 20855, 301-594-1755, FAX 301-594- 1831 FDA Position on the Extra-Label Use of September 14, 1995 Do Do Fluoroquinolones CVM Announces Opinion on Dipyrone December 6, 1995 Do Do Products Regulation of Animal Electronic January 17, 1996 Do Do Identification Products Update on Extra-Label Use of July 16, 1996 Do Do Internet via http:// Fluoroquinolones www.cvm.fda.gov/ Caution Urged in Using Warbex October 4, 1996 Do Do Revised Labeling for Some Medicated January 30, 1997 Do Do Feed Products Colloidal Silver Not Approved For February 12, 1997 Do Do Treating Animals CVM Policy on Competitive Exclusion February 21, 1997 Do Do Products Updated Policy on the Use of Animal March 14, 1997 Do Do Electronic Identification Products in Swine Human Drug Product not Equivalent to July 16, 1997 Do Do Veterinary Ceftiofur FDA Requests That Ball Clay Not be October 14, 1997 Do Do Used in Animal Feeds ---------------------------------------------------------------------------------------------------------------- VII. Guidance Documents Issued by the Office of Policy ---------------------------------------------------------------------------------------------------------------- How to Obtain a Hard Copy of Grouped by Intended the Document (Name and Name of Document Date of Issuance User or Regulatory Address, Phone, FAX, E-mail, Activity or Internet) ---------------------------------------------------------------------------------------------------------------- FDA's Development, Issuance and Use of February 1997 Internal FDA and Internet via www.fda.gov/ Guidance Documents regulated industry opacom/morechoices/ moreindu.html or Office of Policy 301-827-3360 Industry Supported Scientific and December 1997 Regulated industry Internet via www.fda.gov/cder/ Educational Activities guidance/index.htm or Office of Policy 301-827-3360 Draft Guidance on Consumer Directed February 1997 Do Do Broadcast Advertisements Direct Final Rule Guidance November 1997 Internal FDA Internet via www.fda.gov/ opacom/morechoices/industry/ preguide.htm or Marquita Steadman 301-443-3480 Small Entities Compliance Guide On: February 1997 Regulated industry Internet via www.fda.gov/ Regulations to Restrict the Sale and opacom/campaigns/tobacco/ Distribution of Cigarettes and tobret.htm or 1-888-FDA- Smokeless Tobacco in Order to Protect 4KIDS Children and Adolescents (21 CFR Part 897) Children and Tobacco--Frequently Asked July 1997 Do Internet via www.fda.gov/ Questions About the New Regulations- opacom/campaigns/tobacco/ Draft Guidance tobret.htm or 1-888-FDA- 4KIDS Children & Tobacco--A Retailer's Guide October 1997 Do Internet via www.fda.gov/ to the New Federal Regulations opacom/campaigns/tobacco/ tobret.htm or 1-888-FDA- 4KIDS Children & Tobacco--A Guide to the New October 1997 Do Internet via www.fda.gov/ Federal Regulations opacom/campaigns/tobacco/ tobret.htm or 1-888-FDA- 4KIDS FDA's Standards Policy October 1995 Internal FDA and 60 FR 53078, October 11, 1995 regulated industry or Office of Policy 301-827- 3360 ---------------------------------------------------------------------------------------------------------------- [[Page 9841]] VIII. Guidance Documents Issued by the Office of Regulatory Affairs ---------------------------------------------------------------------------------------------------------------- How to Obtain a Hard Copy of Grouped by Intended the Document (Name and Name of Document Date of Issuance User or Regulatory Address, Phone, FAX, E-mail, Activity or Internet) ---------------------------------------------------------------------------------------------------------------- Compliance Policy Guides Manual (PB96- August 1996 FDA Staff Personnel National Technical 915499) Information Service (NTIS), 5285 Port Royal Rd., Springfield, VA 22161 or via Internet at www.fda.gov/ora/ compliance_ref/cpg/ cpgtc.html FDA/ORA International Inspection May 1997 Do FDA, Division of Emergency Manual and Travel Guide and Investigational Operations (HFC-130), 5600 Fishers Lane, Rockville, MD 20857 or via Internet at www.fda.gov/ora/inspect_ref/ itob/itob.html Glossary of Computerized System and August 1995 Do NTIS or via Internet at Software Development Terminology www.fda.gov/ora/inspect_ref/ (PB96-127352) igs/iglist.html Import Alerts continuously Do FDA, Freedom of Information Staff (HFI-35), 5600 Fishers Lane, Rockville, MD 20857, or via Internet at www.fda.gov/ora/fiars/ora_ import_alerts.html Investigations Operations Manual (PB96- May 1996 Do NTIS or via Internet at 913399) www.fda.gov/ora/inspect_ref/ iom/iomtc.html Laboratory Procedures Manual June 1994 Do FDA, Division of Field Science (HFC-141), 5600 Fishers Lane, rm. 12-41, Rockville, MD 20857, ATTN: Denise I. Jones or via Internet at www.fda.gov/ora/ science_ref/lpm/lpmtc.html Regulatory Procedures Manual (PB97- August 1997 Do NTIS or via Internet at 196182) www.fda.gov/ora/compliance_ ref/rpm/rpmtc.html Guide to Inspections of Bulk May 1994 Do NTIS or via Internet at Pharmaceutical Chemicals (PB96- www.fda.gov/ora/inspect_ref/ 127154) igs/iglist.html Guide to Inspections of Pharmaceutical July 1993 Do Do Quality Control Laboratories (PB96- 127279) Guide to Inspections of July 1993 Do Do Microbiological Pharmaceutical Quality Control Laboratories (PB96- 127287) Guide to Inspections of Validation of July 1993 Do Do Cleaning Processes (PB96-127246) Guide to Inspections of Lyophilization July 1993 Do Do of Parenterals (PB96-127253) Guide to Inspections of High Purity July 1993 Do Do Water Systems (PB96-127261) Guide to Inspections of Dosage Form October 1993 Do Do Drug Manufacturers-CGMPs (PB96- 127212) Guide to Inspections of Oral Solid January 1994 Do Do Dosage Forms Pre/Post Approval Issues for Development and Validation (PB96- 127345) Guide to Inspections of Topical Drug July 1994 Do Do Products (PB96-127394) Guide to Inspections of Sterile Drug July 1994 Do Do Substance Manufacturers (PB96-127295) Guide to Inspections of Oral Solutions August 1994 Do Do and Suspensions (PB96-127147) Guide to Inspections of Nutritional February 1995 Do Do Labeling and Education Act (NLEA) Requirements (PB96-127378) Guide to Inspections of Interstate April 1995 Do Do Carriers and Support Facilities (PB96- 127386) Guide to Inspections of Dairy Product April 1995 Do Do Manufacturers (PB96-127329) Guide to Inspections of Miscellaneous May 1995 Do Do Foods Vol. I (PB96-127220) Guide to Inspections of Miscellaneous September 1996 Do Do Foods Vol. II (PB97-196133) Guide to Inspections of Low Acid November 1996 Do Do Canned Foods Manufacturers, Part 1-- Administrative Procedures/Scheduled Processes (PB97-196141) [[Page 9842]] Guide to Inspections of Low Acid April 1997 Do Do Canned Foods Manufacturers, Part 2-- Processes/Procedures (PB97-196158) Guide to Inspections of Cosmetic February 1995 Do Do Product Manufacturers (PB96-127238) Guide to Inspections of Blood Banks September 1994 Do Do (PB96-127303) Guide to Inspections of Source Plasma December 1994 Do Do Establishments (PB96-127360) Guide to Inspections of Infectious June 1996 Do Do Disease Marker Testing Facilities (PB96-199476) Biotechnology Inspections Guide (PB96- November 1991 Do Do 127402) Guide to Inspections of Computerized February 1983 Do Do Systems in Drug Processing (PB96- 127337) Guide to Inspections of Foreign September 1995 Do Do Medical Device Manufacturers (PB96- 127311) Guide to Inspections of Foreign May 1996 Do Do Pharmaceutical Manufacturers (PB96- 199468) ---------------------------------------------------------------------------------------------------------------- IX. International Conference on Harmonization Guidances (CDER) ---------------------------------------------------------------------------------------------------------------- How to Obtain a Hard Copy of Grouped by Intended the Document (Name and Name of Document Date of Issuance User or Regulatory Address, Phone, FAX, E-mail, Activity or Internet) ---------------------------------------------------------------------------------------------------------------- E1A The Extent of Population Exposure March 1, 1995 Do Do to Assess Clinical Safety: for Drugs Intended for Long-Term Treatment of Non-Life-Threatening Conditions E2A Clinical Safety Data Management: March 1, 1995 Do Do Definitions and Standards for Expedited Reporting E2B Data Elements for Transmission of October 1, 1996 Do Do Individual Case Safety Reports E2C Clinical Safety Data Management: May 19, 1997 Do Do Periodic Safety Update Reports for Marketed Drugs E3 Structure and Content of Clinical July 17, 1996 Do Do Study Reports E4 Dose-Response Information to November 9, 1994 Do Do Support Drug Registration E5 Ethnic Factors in the Acceptability July 31, 1997 Do Do of Foreign Clinical Data E6 Good Clinical Practices; May 9, 1997 Do Do Consolidated Guideline E7 Studies in Support of Special August 2, 1994 Do Do Populations: Geriatrics E8 General Considerations for Clinical May 30, 1997 Do Do Trials E9 Statistical Principles for Clinical May 9, 1997 Do Do Trials M3 Timing of Nonclinical Studies for May 2, 1997 Do Do the Conduct of Human Clinical Trials for Pharmaceuticals Q1A Stability Testing of New Drug September 22, 1994 Do Do Substances and Products Q2A Text on Validation of Analytical March 1, 1995 Do Do Procedures Q3A Impurities in New Drug Substances January 4, 1996 Do Do Q5A Biotechnological/Biological May 10, 1996 Do Do Pharmaceutical Products; Viral Safety Evaluation Q6A Specifications; Test Procedures November 25, 1997 Do Do and Acceptance Criteria for New Drug Substances and New Drug Products Chemical Substances Q1B Photostability Testing of New Drug May 16, 1997 Do Do Substances and Products Q1C Stability Testing for New Dosage May 9, 1997 Do Do Forms Q2B Validation of Analytical May 19,1997 Do Do Procedures: Methodology Q3B Impurities in New Drug Products May 19, 1997 Do Do Q5B Quality of Biotechnology Products: February 23, 1996 Do Do Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products Q3C Impurities: Residual Solvents May 2, 1997 Do Do [[Page 9843]] Q5C Quality of Biotechnological July 10, 1996 Do Do Products: Stability Testing of Biotechnology/Biological Products Q5D Quality of Biotechnological/ May 2, 1997 Do Do Biological Products: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products S1A The Need for Long-Term Rodent March 1, 1996 Do Do Carcinogenicity Studies of Pharmaceuticals S3A Toxicokinetics: The Assessment of March 1, 1995 Do Do Systemic Exposure in Toxicity Studies S5A Detection of Toxicity to September 22, 1994 Do Do Reproduction for Medicinal Products S1C Dose Selection for Carcinogenicity March 1, 1995 Do Do Studies of Pharmaceuticals S1C (R) Carcinogenicity Studies of April 2, 1997 Do Do Pharmaceuticals: Addendum to Dose Selection S2A Specific Aspects of Regulatory April 24, 1996 Do Do Genotoxicity Tests for Pharmaceuticals S3B Pharmacokinetics: Guidance for March 1, 1995 Do Do Repeated Dose Tissue Distribution Studies S2B Genotoxicity: Standard Battery April 3, 1997 Do Do Testing S4A Duration of Chronic Toxicity November 18, 1997 Do Do Testing in Animals (Rodent and Nonrodent Toxicity) S5B Detection of Toxicity to April 5, 1996 Do Do Reproduction for Medicinal Products: Addendum on Toxicity to Male Fertility S6 Preclinical Testing of April 4, 1997 Do Do Biotechnology-Derived Pharmaceuticals ---------------------------------------------------------------------------------------------------------------- Dated: February 20, 1997. William B. Schultz, Deputy Commissioner for Policy. [FR Doc. 98-4916 Filed 2-25-98; 8:45 am] BILLING CODE 4160-01-F